Connect public, paid and private patent data with Google Patents Public Datasets

Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically

Download PDF

Info

Publication number
US3850752A
US3850752A US19370271A US3850752A US 3850752 A US3850752 A US 3850752A US 19370271 A US19370271 A US 19370271A US 3850752 A US3850752 A US 3850752A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
enzyme
low
molecular
ml
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
A Schuurs
Weemen B Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/543Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/964Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones

Abstract

The invention relates to a process for the demonstration and determination of a low molecular compound, such as a hapten, or a protein or antibody capable of binding this compound specifically, contacting a fluid containing such a compound or protein to be determined with a given quantity of the coupling product of such a low molecular compound and an enzyme, and with a given quantity of the component to be determined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.

Description

United States Patent [191 Schuurs et al.

[4 ]*Nov. 26, 1974 1 PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klass Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,

[ Notice: The portion of the term of this patent subsequent to Apr. 4, 1989, has been disclaimed.

[22] Filed: Oct. 29, 1971 21 Appl. No.: 193,702

[30] Foreign Application Priority Data Nov. 10, 1970 Netherlands 7016396 [52] US. Cl 195/1035 R, 195/99, 195/63, 424/12 [51] Int. Cl. G01n 31/14, GOln 33/16 8] Field of Search 195/1035 R; 23/253 TP,

[56] References Cited UNITED STATES PATENTS 3,615,222 10/1971 Mead 23/230 B 3,654,090 4/1972 Schuurs et a1. 195/1015 R OTHER PUBLICATIONS Chemical Abstracts 65: ll 124b, (1966). Spector et 11]., 168: 1348. 8. Science," (June 12, 1970).

Primary Examiner-Alvin E. Tanenholtz Attorney, Agent, or Firm-Hugo E. Weisberger [57] ABSTRACT with a given quantity of the component to be deter-- mined, which component is brought in an insoluble form, and determining the enzyme activity of the liquid or solid phase of the resulting reaction mixture.

13 Claims, 6 Drawing Figures PATENT Tia/261974 SHEET 10F 3 O O mu 5 1 N 0.25 0.06 CONCENTRATION ANN-TESTOSTERONE-CELLULOSE (mg/ml) FIG. 2

ng TESTOSTERONE IN THE SAMPLE I PATE NLNNZ SHEET 2M 3 3,850,752

FIG. 3

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O l I l l l 64 I6 4 l 0.25 0.06 CONCENTRATION ANTI-OESTRADIOL-CELLULOSE (mg/ml) FIG 4 5 lm OESTRADIOL 2 J M Q TESTOSTERONLPROGESTERONE gzo- ANTIOESTRADIOL-CELLULOSE sm /mfl ON. L l l I N O 4 I6 64 256 I024 4096 PATEIIIEDIIUVZBIQYI 3.850.752

suecrsor'a FIG.5

IOO

/o ENZYME ACTIVITY IN SUPERNATANT LIQUID O 8 l I l l I I I6 4 I 0.25 0.06 CONCENTRATION OF ANTPFOLATE-CELLULOSE (mg/ml) FIG, 6

Q g, FOLIC ACID l E 80- E z 5 I GLUTAMIC ACID 40- q I g GLY, ASP, LA I 2 I 4 8 I6 32 64 I28 CONCENTRATION IN ng/mI PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY For the determination of low molecular substances occurring in low concentrations, such as steroid hormones in body fluids, methods have been developed using proteins capable of binding the substance to be determined specifically. These methods are based on the competition between the substance to be determined in the sample and a known quantity of the same substance which is labelled radioactive, for a limited quantity of specific binding protein. The unknown quantity of bindable substance then determines what portion of the radioactive labelled substance is bound by the specific binding protein.

It is also possible to determine by these methods an unknown quantity of specific binding protein by reacting a sample containing an unknown quantity of specific binding protein with a given quantity of bindable radioactive labelled substance.

in the literature it is common practice to distinguish these determination methods according to the nature of the specific binding protein employed, although the underlying principle of all determinations is identical. Thus, for example, they speak of competitive protein binding assays when they employ receptor or transport proteins occurring in the body, and of radioimmunological determinations when they employ antisubstances.

For both types of determinations radioactive labelled substances are required. The work with these substances requires the presence of precious measuring apparatuses, good laboratory facilities and a highly qualified staff. These high requirements prevent a general application of these determination, especially in smaller laboratories.

A process has now been found for the demonstration and determination of a component of the reaction between a low molecular compound and a protein capable of binding this compound specifically using the binding affinity of such components for each other,

characterized in that the determination is performed with a given quantity of the coupling product of the low molecular compound and an enzyme, and with a given quantity of a component of the said reaction which has been made insoluble, and the enzyme activity of the liquid or the solid phase of the resulting reaction mixture is determined, which activity is a measure for the quantity of the reaction component to be determined.

The method found can often by employed for the determination of haptens, which may be regarded as a special group of low molecular compounds, and their anti-substances. These substances mostly occur in low concentrations. According to the original definition of K. Landsteiner haptens are protein-free substances whose chemical configuration is such that they can react with specific antibodies, but not such that they are capable of causing the formation of anitbodies. In order to be able yet to make antibodies against haptens, the haptens must be coupled to polypeptides before being injected into the test animal. In the determination of a low molecular compound the substance to be determined and its coupling product with an enzyme enter into competition for a given quantity of the insoluble specific binding protein. The more low molecular compound the sample contains, the less opportunity the soluble enzyme conjugate of that compound has to combine with the insoluble specific binding protein and the more of the conjugate will remain in the liquid phase, in which the enzyme activity can be measured in a simple manner.

In the determination of a specific binding protein with the same reagents the soluble protein to be determined and the insoluble protein enter into competition for a given quantity of the conjugate of the corresponding low molecular compound and an enzyme. If the content of specific binding protein of the sample is higher, the insoluble protein will bind less of the enzyme conjugate, and consequently more enzyme remains in the liquid phase.

A specific binding protein having two or more binding possibilities can also be demonstrated and determined according to the invention, i.e. with the enzyme conjugate and. with the low molecular compound in an insoluble form. The liquid phase of the reaction mixture then contains the conjugate bound to the specific binding protein and in the solid phase the complex of enzyme conjugate specific binding protein insoluble low molecular compound. The more of the protein to be determined there is in the sample, the more enzyme activity the liquid phase will possess.

By means of an assay curve for a certain system in which increasing contents of substance to be determined have been set off against the enzyme activity found, preferably in the liquid phase, the quantity of substance to be determined in the sample can be derived from a value of enzyme activity found.

The most important reagents of this detennination method is the coupling product of the low molecular substance and an enzyme, for convenience hereinafter also called enzyme conjugate, which on the one hand can react with the specific binding protein, via the low molecular component and on the other hand possesses enzyme activity. This reagent is prepared by a method described for similar products. The second reagent, the insoluble component in the reaction system, serves to facilitate the separation between various enzymecontaining fractions of the reaction mixture. Addition of this reagent causes the fonnation of a solid phase in addition to a liquid phase. The present determinations can in principle be performed without an insoluble component of the reaction system. In that case the various fractions with enzyme activity will have to be separated by, for example, chromatographic or electrophoretic route or gelfiltration. For practical reasons such a determination is less attractive, however,

The enzyme activity of a fraction of the reaction mixture is demonstrated or measured by incubating that fraction with a substrate and other substances required for processing the relative enzyme: reaction. For preference a reaction is used in which a coloured compound is formed or removed whose absorption can also be measured quantitatively in an easy manner.

Low molecular substances which are eligible for demonstration by the new method and have a molecular weight of up to about 1500 are for example: steroids, vitamin B folinic acid, thyroxine and triiodothyronine, releasing factors, histamine, serotonin and other biogenic amines, digoxine, digitoxin, prostaglandins, adrenalin, nor-adrenalin, vegetable hormones such as auxin, kinetin and gibberellic acid, and antibiotics such as penicillin.

The method of demonstrating specific binding proteins for low molecular substances can be employed for, for example, the determination of antibody against penicillin or for the determination of intrinsic factor.

The preparation of conjugates of enzymes and lowmolecular substances can take place in various manners. Some low molecular substances may already possess groups that can be cross-linked with reactive groups at the surface of the enzyme, while other substances will have to be provided with such groups by organic chemical reactions. It stands to reason that the original binding properties of the low molecular compound and the activity of the enzyme may not change essentially during this process. The groups of the enzyme which are particularly suited for coupling reactions are amino and carboxyl groups. If the modified or unmodified low molecular substance also possesses such groups, the coupling can be performed by, for example, reactions known from the peptide synthesis. Furthermore such substances as glutaraldehyde, difluorodinitrodiphenylsulfon, toluene diisocyanate, diand trichloros-triazine can be employed for the coupling reaction.

Specific examples of the coupling of haptens to proteins are described in, for example, Methods in Immunology and lmmunochemistry, vol. I. The methods described are used for the preparation of conjugates for immunisation but they can also be used for the preparation of conjugates of the low molecular substance and an enzyme which are essential in the invention.

The choice of the enzyme that is to be a component of the conjugate (low molecular substance-enzyme) depends on properties such as the specific activity (a high conversion rate enhances the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme which catalyses a conversion involving coloured reaction components, is simple. Such colorimetric determinations can be automatized in a simple manner.

According to the invention it is also possible to use enzymes which catalyse conversions involving reaction components that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automatized.

For the preparation of the conjugates enzymes such as catalase, peroxidase, B-glucuronidase, fl-D- glucosidase, B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, particularly the group of the oxide reductases.

The insoluble specific binding protein or the insoluble low molecular compound to be used in the present determination can be prepared by a known method, for example, by cross-linking with chloroformic acidethylester, by covalent binding with insoluble carriers such as agarose, cross-linked dextran or filter paper, or by physical coupling to insoluble carriers such as plastic objects.

The form in which the reagents can be used are manifold. The component of the reaction system conjugated with an enzyme can be freeze-dried or dissolved in a buffer. Furthermore a solid carrier, for example, a strip of paper impregnated with the conjugate, can be employed.

The insoluble component can be brought in the form of particles of various sizes, such as grains, platelets and rods, or in the form of a strip of some or other carrier material.

For the performance of the process according to the invention a test pack in preferably employed, chiefly composed of:

a. a given quantity of the coupling product of the low molecular compound and an enzyme;

b. a corresponding quantity of one of the components of the reaction system in an insoluble form;

c. a substrate for the determination of the activity of the enzyme employed.

If required, the test pack can also contain the necessary auxiliaries for making a dilution series of the sample to be examined for a quantitative determination, such as test tubes, pipettes and flasks of diluent. For the determination of a hapten or its antibody the test pack contains at least:

a. a given quantity of the coupling product of this hapten and an enzyme;

b. a corresponding quantity of a component of the reaction system in an insoluble form, haptenantibody;

c. a substrate for the determination of the enzyme activity.

The invention is illustrated further by the following examples, which are not to be construed as limiting.

Example I Determination of testosterone A. Preparation of testosterone-S-HRP One hundred milligrams of testosterone-3-(O-carboxymethyl)-oxim and 0.143 ml of tri-nbutylamine were dissolved in 5 ml of dioxan. The solution was cooled down to 2C and then 0.03 ml of isobutylchlorocarbonate were added. After 30 minutes the solution was added to mg of HRP (horse radish peroxidase) in a mixture of 9 ml of water and 6 ml of dioxan, and adjusted to pH 9 with 0.1 N NaOH. This solution was stirred for 4 hours at 2C and dialysed overnight. The precipitate obtained after the dialysate had been adjusted to pH 4.6 was centrifuged after having been left to stand overnight, suspended in 10 ml of water and dissolved by means of caustic soda solution. The material was precipitated three times with 15 ml of acetone at pH 4.5, dissolved in 15 ml of water which had been adjusted at pH 7.8 with caustic soda solution, dialysed and finally lyophilized.

B. Preparation of testosterone-Zl-BSA This conjugate was prepared in the same manner as the testosterone-B-HRP, but the starting materials were 50 mg of testosterone-3-(O-carboxymethyl)- oxim and mg of BSA (bovine serum albumin).

C. Preparation of antibodies against testosterone-3- BSA Five rabbits were injected intrarnuscularly with increasing dosages of testosterone-3-BSA in complete Freunds adjuvant (0.5, 1 and 2 mg) at intervals of 3 weeks. Two weeks after the last injection the animals were injected intravenously with 2 mg of antigen dissolved in physiological salt. One week after that blood was taken from the animals. The antibodies formed against BSA were removed by treating the serum portionwise with BSA-maminobenzyloxymethyl cellulose, prepared in accordance with Gurvichs method (see D). D. Preparation of anti-testosterone cellulose This substance was prepared in accordance with Gurvichs method as described in Biokhimiya 26, 934 (1961):

1. Preparation of aminocellulose:

Fifty grams of Whatman cellulose, which had been frequently washed and decanted, were suspended in 100 ml of a 0.7 sodium acetate solution containing 2 gm of N(m-nitrobenzoxy methylpyridine. The mixture was dried at 6080C and heated for 40 minutes at 125C. The resulting product was thoroughly washed with distilled water, dried at 80C, washed with benzene and dried again. Fifty grams of the dried product were reduced by suspension in 300 ml of a 15% Na S O solution and stirred for 30 minutes at 5060C. The product was filtered and washed with successively distilled water, 30% acetic acid and again with distilled water.

2. Treatment with ammoniacal copper solution:

Forty millilitres of sulphuric acid, 20 ml of 50% nitric acid and 140 ml of distilled water were heated, while stirring, to 90C, after which 5.9 gm of CuO were added in small portions. The solution was boiled for 2 hours and completed to 500 ml with distilled water. Eighty millilitres of this solution were transferred into an icebath and added to 160 ml of cold 4 N NaOI-I, while stirring. After being stirred for 30 minutes, the precipitate was washed twice with distilled water and dissolved in 80 ml of 25% ammonia. To this solution was gradually added 1 gm of aminocellulose. The mixture was stirred for 1.5 hours, after which 40 ml of boiling water were added, whereupon the solution was quickly cooled down to 0C. The solution was neutralized with 10% sulphuric acid, after whichthe aminocellulose flocculated. It was washed with cold distilled watel.

3. Preparation of 'y-globulin:

To rabbit anti-testosterone serum were added 180 mg of Na SO per ml of serum. The mixture was stirred for 1 hour at room temperature, after which the resulting precipitate was centrifuged, washed twice with an 18% Na SO solution and taken up in so much 0.05 M sodium borate of pH 8.6 that the protein concentration was about 10 mg/ml.

4. Binding 'y-globulin to aminocellulose Aminocellulose (350 mg) was suspended in distilled water (50 ml). The suspension was cooled down to 0C. Ten millilitres of a 36% hydrochloric acid were added and after that dropwise 10 ml of a 10% NaNO solution. The suspension was centrifuged, washed with cold distilled water and then with 0.05 M sodium borate of pH 8.6. The cellulose was suspended in 43 ml of 0.05 M sodium borate of pH 8.6. To this suspension were added 7 ml of the 'y-globulin solution prepared. The mixture was stirred for 26 hours at 4C, centrifuged and washed with 0.02 M phosphate buffer of pH 6.0. From the antiserum of each of the 5 immunized rabbits a cellulose suspension was prepared (A E respectively).

E. Determination of testosterone by means of testosterone-3-HRP and anti-testosterone cellulose The following test system was built up: I Immunoreaction buffer of pH 6.0 and containing 2% sheep serum.

II Enzyme reaction 0.5 ml of the supernatant liquid was incubated at room temperature with 1.5 ml of substrate for 30 minutes. The extinction was measured at 460 nm.

The enzyme substrate contained 10 ,ul of 30% hydrogen peroxide and 20 mg of S-aminosalicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6.2.

FIG. 1 shows the measure in which testosterone3- HRP is bound by the anti-testosteronecellulose preparations made. In this case only buffer was added as a sample in the test system. If cellulose is added instead of anti-testosterone-cellulose, more than of the enzyme activity will remain behind in the supernatant liquid. The preparations B, D and E proved to bind hardly any testosterone-3- HRP, but A and C did.

FIG. 2 shows the results of incubation of a testosterone dilution series with testosterone-3-HRP and four different concentrations of anti-testosteronecellulose C 1 mg/ml (I), 2 mg/ml (II), 4 mg/ml (III) and 16 mg/ml (IV). It is obvious that with this system a quantity of about 10 ngm of testosterone can be demonstrated.

EXAMPLE III Determination of ,oestradiol A. Oestradiol-l7-succinyl-HRP was prepared by the mixed anhydride method described in example I A, using 50 mg of oestradiol-l7-hemisuccinate and 50 mg of HRP as starting materials.

B. Oestradiol-17-succinyl-BSA was prepared by the mixed anhydride method described in example I A, using mg of oestradiol-l7-hemisuccinate and mg of BSA as starting materials.

C. For the preparation of antibodies against oestradiol-l7-succinyl-BSA five rabbits were immunized in accordance with the scheme described in example I C. The sera were absorbed with BSA- m-amino-benzyloxymethyl-cellulose.

D. Anti-oestradiol-cellulose was prepared in the same manner as the anti-testosterone-cellulose described in example I D. From each of the immunized rabbits a cellulose preparation was made, numbered 16 up to 20 inclusive.

E. The test was performed analogous to that for testosterone as described in example I E.

FIG. 3 and 4 show a few results. FIG. 3 shows that the immunization yielded 3 usable antisera, of which As 17 has the highest titre.

FIG. 4 shows the test system in which anti-oestradiolcellulose 17 is used in a concentration of 8 mg/ml. The system does not discriminate between oestron and 17B-oestradiol. 17a-oestradiol and especially oestriol show a smaller cross-reaction. Testosterone and progesterone influence the system only in very high concentrations.

Example Ill Determination of antibodies against penicillin Penicilloyl-catalase Thirty milligrams of benzyl penicillinic acid were dissolved in ml of 96% ethanol and added dropwise to 200 mg of catalase in 45 ml of 0.1 M phosphate buffer of pH 7.5. The reaction process was continued for 2 hours, the pH being maintained between 7.2 and 8.2 with 0.5 N NaOH. The reaction mixture was dialysed against 6 X 3 l of 0.02 M phosphate buffer of pH 7.0.

In the same manner 250 mg of benzyl penicillinic acid were coupled to 5 gm of m-aminobenzyloxymethyl-cellulose prepared by Gurvichs method. Biokhimiya 26, 934 (1961). The coupling product was not dialysed however, but washed on a glass filter.

It proved to be possible to demonstrate over -sensitiveness to penicillin in humans in the following manner.

0.2 ml of a sample of non-haemolysed serum were mixed with 0.5 ml of a solution of penicilloyl-catalase (1 800). After 30 minutes mg of the penicilloyl-maminobenzyloxymethyl-cellulose were added. The mixture was rotated, for 30 minutes after which the enzyme activity in the supernatant liquid was determined by adding 0.02 ml of it to 2.8 ml of 0.05 M phosphate buffer of pH 6.8, which contained 1.2 a] of 30% H 0 and following the decrease in the extinction at 240 nm. In the serum from patients who were hyper-sensitive to penicillin less enzyme activity was found in the liquid than in checking with rabbit serum. The serum from normal human beings in these tests did not deviate considerably from normal rabbit serum.

Example IV Determination of folic acid A. Preparation of folate-glucose-oxidase Two hundred milligrams of glucose-oxidase (140 lU/mg) were dissolved in 10 ml of PBS (phosphate buffered saline, a phosphate-containing physiological salt solution) of pH 7.0. Thirty milligrams of l-cyclohexyl-3-( 2-morpholino-ethyl carbodiimide (MCDI) were added and then 24 mg of folic acid. The reaction process lasted 2 hours, after which a thorough dialysis was performed against PBS of pH 7.0.

B. Preparation of folate-MBSA (methylated bovine serum albumin) Folate-MBSA was prepared by Ricker and Stollars process described in Biochemistry 6, 2001 (1967). Twenty-five milligrams of MCDI were added to 50 mg of MBSA in 5 ml of water and then mg of folic acid. Two hours later a yellow precipitate had formed. Finally the whole reaction mixture was dialysed against physiological salt for a considerable time.

C. Preparation of antiserum against folate-MBSA On the days 0, 21 and 42 four rabbits were each injected intramuscularly with 2 mg of folate-MBSA in complete Freunds adjuvant and on day 35 intravenously with 2 mg of folate-MBSA in physiological salt. On day 49 the animals were exsanguinated.

D. Anti-folate cellulose was prepared by the process described in example I D.

E. Test system for folic acid One hundred ul of sample and 700 p.l of anti-folate cellulose suspension were rotated for 3 hours. Two hundred ul of folate-glucose-oxidase (l 1500) were added. The mixture was rotated again for 3 hours and centrifuged, after which the enzyme activity in the supernatant liquid was determined. This was done by mixing 0.5 ml ofit with a solution of 50 mg of glucose, 10 ,ugm of HRP and 1 mg of 5-aminosalicylic acid in 2.5 ml of 0.05N phosphate buffer of pH 6.0 and measuring the extinction after 30 minutes at 460 nm.

FIG. 5 shows the percentage of enzyme bound against the concentration of an anti-folatecellulose.

FIG. 6 shows the sensitivity of the test system in an anti-folate-cellulose concentration of 2 mg/ml and the effect of glycine, asparagine, alanine and glutamic acid.

Example V Determination of digoxin A. Preparation of digoxin-HRP To 22 mg of digoxin, suspended in 1 ml of absolute ethanol, was added dropwise, while stirring, 1 ml of 0.1 M sodium metaperiodate. After 25 minutes 0.3 ml of 0.1 M ethyleneglycol was added. Five minutes later this mixture was added dropwise, while stirring, to a solution 32 mg of horse radish peroxidase (HRP) in 1 ml of distilled water, which had been adjusted to pH 9.5 with a 5% K CO solution. During the reaction the pH was maintained at 9-9.5 with 5% K CO When the pH had become stable 15 mg of NaBH, in 1 ml of distilled water was added. After 3 hours the pH was adjusted to 6.5 with l M formic acid. One hour later 1 M NH OH was added till a pH of 8.5 had been reached. The mixture was dialysed overnight against cold running water. Finally the pH was adjusted at 4.5 with 0.1 N hydrochloric acid. The mixture was left to stand at room temperature for 1 hour and 4 hours at 4C to obtain a precipitate which was centrifuged for 1 hour at 1000 g. The precipitate was dissolved in 5 ml of 0.1 M Nail-[C0 thoroughly dialysed and freeze-dried.

B. Preparation of digoxin-BSA Digoxin bovine serum albumin (BSA) was prepared in the same manner as the above digoxin-HRP, but the starting materials were 436 mg of digoxin and 560 mg of BSA, the quantities of the other reagents having been raised in the same ratio as the digoxin.

C. Preparation of antibodies against digoxin Five rabbits were each injected with 400, 800 and 1600 ugm of digoxin-BSA respectively, at fortnightly intervals. The immunogen was mixed with complete Freunds adjuvant and administered intramuscularly. A fortnight after the last injection the animals were injected intravenously with 800 ugm of digoxin-BSA in physiological salt. Ten days later the animals were bleeded. The serum was adsorbed with BSA-m-aminobenzyloxymethylcellulose. D. Preparation of anti-digoxin-cellulose Anti-digoxin-cellulose was prepared by Gurvichs method as described in example 1 D. E. Determination of digoxin A dilution series was prepared of digoxin in 0.1 M phosphate buffer of pH 7.5 containing 0.9% NaCl, 0.5% Tween-20 and 1.0% of BSA. The dilution series was of from 0.1-100 ngm/ml. One millilitre of a digoxin solution was mixed with 0.1 ml of digoxin-HRP in a suitable dilution, after which 2 mg of antidigoxin-cellulose suspended in 0.4 ml of buffer were added. The mixture was rotated for 6 hours at room temperature, after which it was centrifuged and the enzyme activity in the supernatant liquid determined.

Addition of 0.8 ngm of digoxin proved to cause a measurable increase of enzyme activity in the supernatant liquid. Digitoxin only showed a slight cross-reaction in the system whereas cholesterol, cortisol, oestradiol, testosterone and progesterone did not show any cross-action in the system.

Example VII Determination of transcortine The reagents used for the determination of cortisol, as described in Example IV, were also employed for the determination of transcortine.

Of a dilution series of transcortine of from O 1280 ngm/ml 0.5 ml was incubated for 15 minutes at 4C with 0.2 ml of cortisol-2l-galactose-oxidase in a suit- 10 able dilution. To this dilution series 0.3 ml of transcortine-Sepharose mg/ml) were added and the mixture was rotated for 15 minutes at 4C. The activity in the supernatant liquid was measured as described in example VI. 15 A sample containing 40 ngm/ml of transcortine proved to cause a measurable increase of enzyme activity in the supernatant liquid, whereas in the presence of 320 ngm/ml all the enzyme activity was found in the supernatant liquid.

What is claimed is:

1. Process for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight compound, comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. providing a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound;

Example VI Determination of cortisol A. Preparation of cortisol-2l-galactose-oxidase Fifty mg of cortisol-Zl-hemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride technique as described in example I A. B. Preparation of insoluble transcortine One hundred milligrams of transcortine, purified by DEAE, cellulose, and hydroxyl apatite chromatography respectively, were coupled to 3 gm Sepharose 4 B by the CNBr method, as follows. Three grams of Sepharose 4 B suspension were activated by mixing it with 4 ml of a 2.5% (w/v) CNBr solu tion in distilled water, after which the pH was adjusted between 10 and 11 with 1 N NaOI-l, at which value it was maintained for 6 minutes. The Sepharose was washed with icewaterand with 0.1 M NaHCO Then 100 mg of transcortine in 20 ml of 0.1 M NaHCO were added and the suspension was shakenfor 24 hours at 4C. After being washed with'successively 0.5 M NaI-ICO 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer,

2. The process of claim 1 in which said low molecular weight organic compound is a hapten.

3. The process of claim 1 in which said enzyme is an oxido-reductase.

4. Process for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound specifically, comprising the steps of:

to which 0.1% merthiolate had been added. C. Determination of cortisol Of a cortisol-containing sample (standard, plasma or urine) 0.5 ml were extracted twice with methylene chloride (2 X 3 ml). The combined extraction liquids wereevaporated to dryness. The residue was .a. providing a given quantity of the coupling product taken up in 0.5 ml of physiological salt solution and mixed with 0.2 ml of cortisol-2l-galactose-oxidase s z i :Z ggi wlght orgamc compound m a.smtable concentraum? and 1 b. providing a corresponding given quantity of an incomne'sepharose Suspens lon (5 solubilized specific binding protein having more ture was rotate? for mmutes and cenm' than one valency capable of reacting to bind said fuged, after which the enzyme activity in the superlow molecular weight organic compound specifb natant liquid was determined by adding 0.5 m1 of Cally;

it to m1 of Substrate cotlsistillg 9 mg of c. contacting a sample of a fluid containing the low galactose, zofng S'ammOSahCYhC and 10 molecular weight organic compound to be deterof Permdase 150 ml of 002 M Phosphate mined with said components (a) and (b) to form a buffer of pH 6.0. Thirty minutes later the extinction was measured at 460 nm.

Five ngm/ml of cortisol in the sample caused a measurable increase of the enzyme activity in the supernatant liquid. Corticosterone and progesterone 6 reaction mixture; and

d. determining the enzyme activity of the liquid or the solid phase of the resulting reaction mixture, which activity is a measure of the quantity of low molecular weight organic compound to be deter mined.

5. The process of claim 4 in which said enzyme is an oxido-reductase.

6. Process for the demonstration and determination of a specific binding protein having two or more binding sites by means of a low molecular weight organic compound capable of reacting to bind said protein specifically; comprising the steps of:

a. providing a given quantity of the coupling product of said low molecular weight organic compound and an enzyme;

b. providing a corresponding given quantity of an insolubilized specific binding protein having two or more binding sites capable of binding said low molecular weight organic compound;

c. contacting a sample of a fluid containing the protein to be determined with said components (a) and (b) to form a reaction mixture; and

d. determining the enzyme activity of the liquid phase of the resulting reaction mixture, which activity is a measure of the quantity of the specific binding protein to be determined.

7. The process of claim 6 in which said protein is an antibody.

8. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight organic compound, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound; and

c. a substrate for the determination of the enzyme activity of said enzyme.

9. The diagnostic pack of claim 8 in which said enzyme is an oxido-reductase.

10. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low molecular weight organic compound spe cifically, comprising:

a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme;

b. a corresponding given quantity of an insolubilized specific binding protein capable of reacting to bind said low molecular weight organic compound specifically; and

c. a substrate for the determination of the enzyme activity of said enzyme.

11. The diagnostic pack of claim 10 in which said enzyme is an oxido-reductase.

12. A diagnostic pack for the demonstration and determination of a hapten by means of an antibody against said hapten, comprising:

a. a given quantity of the coupling product of said hapten with an enzyme;

b. a corresponding given quantity of an insolubilized antibody against said hapten; and

c. a substrate for the determination of the enzyme activity of said enzyme.

13. The diagnostic pack of claim 12 in which said enzyme is an oxido-reductase.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 A Page: 1 of 2 DATED November 26, 1974 vE 0 (5) Schuurs et a1.

It is certified that error appears in the above-identifiedpatent and that said Letters Patent is hereby corrected as shown below:

On the front page of the patent (disclosing the inventors, assignee, Abstract, References Cited, under [21] Appl No. 193,702" the following heading and contents thereunder:

Related U.S. Application Data p In column 1, beneath the title "PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF LOW MOLECULAR COMPOUNDS AND OF PROTEINS CAPABLE OF BINDING THESE COMPOUNDS SPECIFICALLY" Insert the following paragraph:

This application is a continuation-in-part of Ser. No. 762,120, filed September '24, 1968, issued as U.S. Pat. 3,654,090 on April 4, 1972.

In column 4, line 25, change to In column 5, lines 31 32, place "aminocellulose" in quotation marks. I

In column 5, line 48, place "aminocellulose" in quotation marks.

In column 5, line 49, place "aminocellulose" in quotation marks.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,850,752 Page 2 of 2 DATED November 26, 1974 INVENTQR(S) Schuurs et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 7, line 20, change to "z".

Signed and Scaled this Twelfth Day Of Ju1y1983 [SEAL] A nest:

GERALD J. MOSSINGHOFF Arresting Officer Commissioner of Parents and Trademarks

Claims (13)

1. PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF A LOW MOLECULAR WEIGHT ORGANIC COMPOUND BY MEANS OF AN ANTIBODY AGAINST SAID LOW MOLECULAR WEIGHT COMPOUND, COMPRISING THE STEPS OF: A. PROVIDING A GIVEN QUANTITY OF THE COUPLING PRODUCT OF SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND WITH AN ENZYME; B. PROVIDING A CORRESPONDING GIVEN QUANTITY OF AN INSOLUBILIZED ANTIBODY AGAINST SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND; C. CONTACTING A SAMPLE OF A FLUID CONTAING THE LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED WITH SAID COMPONENTS (A) AND (B) TO FORM A REACTION MIXTURE; AND D. DETERMINING THE ENZYME ACTIVITY OF THE LIQUID OR THE SOLID PHASE OF THE RESULTING REACTION MIXTURE, WHICH ACTIVITY IS A MEASURE OF THE QUANTITY OF LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED.
2. The process of claim 1 in which said low molecular weight organic compound is a hapten.
3. The process of claim 1 in which said enzyme is an oxido-reductase.
4. PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF A LOW MOLECULAR WEIGHT ORGANIC COMPOUND BY MEANS OF A PROTEIN CAPABLE OF REACTING TO BIND SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND SPECIFICALLY, COMPRISING THE STEPS OF: A. PROVIDING A GIVEN QUANTITY OF THE COUPLING PRODUCT OF SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND WITH AN ENZUME; B. PROVIDING A CORRESPONDING GIVEN QUANTITY OF AN INSOLUBILIZED SPECIFIC BINDING PROTEIN HAVING MORE THAN ONE VALENCY CAPABLE OF REACTING TO BIND SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND SPECIFICALLY; C. CONTACTING A SAMPLE OF A FLUID CONTAINING THE LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED WITH SAID COMPONENTS (A) AND (B) TO FORM A REACTION MIXTURE; AND D. DETERMING THE ENZYME ACTIVITY OF THE LIQUID OR THE SOLID PHASE OF THE RESULTING REACTION MIXTURE, WHICH ACTIVITY IS A MEASURE OF THE QUANTITY OF LOW MOLECULAR WEIGHT ORGANIC COMPOUND TO BE DETERMINED.
5. The process of claim 4 in which said enzyme is an oxido-reductase.
6. PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF A SPECIFIC BINDING PROTEIN HAVING TWO OR MORE BINDING SITES BY MEANS OF A LOW MOLECULAR WEIGHT ORGANIC COMPOUND CAPABLE OF REACTING TO BIND SAID PROTEIN SPECIFICALLY; COMPRISING THE STEPS OF: A. PROVIDING A GIVEN QUANTITY OF THE COUPLING PRODUCT OF SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND AND AN ENZYME; B. PROVIDING A CORRESPONDING GIVEN QUANTITY OF AN INSOLUBILIZED SPECIFIC BINDING PROTEIN HAVING TWO OR MORE BINDING SITES CAPABLE OF BINDING SAID LOW MOLECULAR WEIGHT ORGANIC COMPOUND; C. CONTACTING A SAMPLE OF A FLUID CONTAINING THE PROTEIN TO BE DETERMINED WITH SAID COMPONENTS (A) AND (B) TO FORM A REACTION MIXTURE; AND D. DETERMINING THE ENZYME ACTIVITY OF THE LIQUID PHASE OF THE RESULTING REACTION MIXTURE, WHICH ACTIVITY IS A MEASURE OF THE QUANTITY OF THE SPECIFIC BINDING PROTEIN TO BE DETERMINED.
7. The process of claim 6 in which said protein is an antibody.
8. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of an antibody against said low molecular weight organic compound, comprising: a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme; b. a corresponding given quantity of an insolubilized antibody against said low molecular weight organic compound; and c. a substrate for the determination of the enzyme activity of said enzyme.
9. The diagnostic pack of claim 8 in which said enzyme is an oxido-reductase.
10. A diagnostic pack for the demonstration and determination of a low molecular weight organic compound by means of a protein capable of reacting to bind said low Molecular weight organic compound specifically, comprising: a. a given quantity of the coupling product of said low molecular weight organic compound with an enzyme; b. a corresponding given quantity of an insolubilized specific binding protein capable of reacting to bind said low molecular weight organic compound specifically; and c. a substrate for the determination of the enzyme activity of said enzyme.
11. The diagnostic pack of claim 10 in which said enzyme is an oxido-reductase.
12. A diagnostic pack for the demonstration and determination of a hapten by means of an antibody against said hapten, comprising: a. a given quantity of the coupling product of said hapten with an enzyme; b. a corresponding given quantity of an insolubilized antibody against said hapten; and c. a substrate for the determination of the enzyme activity of said enzyme.
13. The diagnostic pack of claim 12 in which said enzyme is an oxido-reductase.
US3850752A 1970-11-10 1971-10-29 Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically Expired - Lifetime US3850752A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL7016396A NL154598B (en) 1970-11-10 1970-11-10 Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.

Publications (1)

Publication Number Publication Date
US3850752A true US3850752A (en) 1974-11-26

Family

ID=19811504

Family Applications (1)

Application Number Title Priority Date Filing Date
US3850752A Expired - Lifetime US3850752A (en) 1970-11-10 1971-10-29 Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically

Country Status (10)

Country Link
US (1) US3850752A (en)
BE (1) BE775187A (en)
CA (1) CA967464A (en)
DE (1) DE2155658C3 (en)
DK (1) DK140268C (en)
ES (1) ES396741A1 (en)
FI (1) FI54033C (en)
FR (1) FR2113733A5 (en)
GB (1) GB1348935A (en)
NL (1) NL154598B (en)

Cited By (1096)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905871A (en) * 1971-05-14 1975-09-16 Syva Co Lactam conjugates to enzymes
US3966556A (en) * 1972-11-06 1976-06-29 Syva Company Compounds for enzyme amplification assay methadone analogs
US3975237A (en) * 1972-11-06 1976-08-17 Syva Company Compounds for enzyme amplification assay - - ecgonine analogs
US4039385A (en) * 1972-05-08 1977-08-02 Syva Company Cardiac glycoside enzyme conjugates
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4043872A (en) * 1975-02-20 1977-08-23 Syva Company Polyiodothyronine immunoassay
US4046636A (en) * 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
FR2367286A1 (en) * 1976-10-07 1978-05-05 Mochida Pharm Co Ltd New process and immunochemical assay reagents physiologically active substances
US4096138A (en) * 1975-12-08 1978-06-20 Scherr George H Immunological test procedure
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
DE2805961A1 (en) * 1977-04-15 1978-10-19 Syva Co Theophylline antigens and antibodies and their use for determination of theophylline
FR2390732A1 (en) * 1977-05-12 1978-12-08 Sclavo Inst Sieroterapeut A method for determining the levels of certain components of biological fluids and means implemented
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
US4166767A (en) * 1976-03-25 1979-09-04 Dainippon Pharmaceutical Co., Ltd. Insolubilized antibody
US4191613A (en) * 1971-05-14 1980-03-04 Syva Company Malate dehydrogenase conjugates for enzyme immunoassays
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
WO1980002747A1 (en) * 1979-05-31 1980-12-11 Rapidex Ltd Ultrasensitive enzymatic radioimmunoassay method
US4250253A (en) * 1977-03-15 1981-02-10 Snamprogetti S.P.A. Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
US4269938A (en) * 1979-03-08 1981-05-26 Eastman Kodak Company Assay of peroxidatively active materials
US4282325A (en) * 1971-05-14 1981-08-04 Syva Company Enzyme bound corticosteroids
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
US4347312A (en) * 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
US4350761A (en) * 1979-05-18 1982-09-21 Yamasu Shoyu Kabushiki Kaisha Method of and reagents for quantitative analysis of cyclic nucleotides
WO1982004323A1 (en) * 1981-06-02 1982-12-09 O Neill Sean Immunoprecipitation assay
US4376825A (en) * 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4419453A (en) * 1981-09-28 1983-12-06 The Dow Chemical Company Immunological agglutination assays with dyed or colored latex and kits
US4443365A (en) * 1980-07-01 1984-04-17 Dainippon Pharmaceutical Company Limited Method for determination of the valproic acid and reagents therein
US4467030A (en) * 1978-06-12 1984-08-21 Boehringer Mannheim Gmbh Determination of the thyroxine-binding index in serum
WO1985000605A1 (en) * 1983-07-27 1985-02-14 American Hospital Supply Corporation Process for selective nitrile reduction
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
US4535057A (en) * 1982-07-26 1985-08-13 Amf Incorporated Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4786594A (en) * 1986-05-14 1988-11-22 Syntex (U.S.A.) Inc. Enzyme immunoassay
US5047330A (en) * 1983-08-17 1991-09-10 Commissariat A L'energie Atomique Compound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
EP0524502A2 (en) 1991-07-22 1993-01-27 Bayer Corporation Immunoassay for free analyte
US5268298A (en) * 1991-04-26 1993-12-07 Life Technologies, Inc. System for delivering oxygen to a cell culture medium
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5391483A (en) * 1990-07-27 1995-02-21 Eastman Kodak Company Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
EP0699754A1 (en) 1994-08-12 1996-03-06 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
EP0703296A1 (en) 1988-09-29 1996-03-27 Chiron Corporation Polynucleotide determination by strand replacement of a capture probe
EP0705903A1 (en) 1994-08-12 1996-04-10 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US5587294A (en) * 1991-07-19 1996-12-24 Assay Research, Inc. Method and kit for measuring endogenous cytokines
US5589344A (en) * 1994-06-15 1996-12-31 Johnson & Johnson Clinical Diagnostics, Inc. Test kit and method for competitive specific binding assay
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5637467A (en) * 1992-10-13 1997-06-10 Behringwerke Ag Heterogeneous assay using a pendulous drop
EP0785216A1 (en) 1995-12-18 1997-07-23 Myriad Genetics, Inc. Chomosome 13-linked breast cancer susceptibility gene BRCA2
US5652346A (en) * 1990-07-27 1997-07-29 Johnson & Johnson Clinical Diagnostics, Inc. Dicarboxylic acid oxidation products
US5684144A (en) * 1993-07-28 1997-11-04 University Of North Texas Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
US5717074A (en) * 1988-09-02 1998-02-10 The Rockefeller University Macrophage-derived inflammatory mediator (MIP-2)
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
WO1998014593A2 (en) 1996-10-01 1998-04-09 Geron Corporation Human telomerase catalytic subunit
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5837535A (en) * 1994-06-13 1998-11-17 Henry Ford Health System Neuronal-neonatal gene: neuronatin
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US5876928A (en) * 1978-04-13 1999-03-02 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5939524A (en) * 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
WO1999045124A2 (en) 1998-03-04 1999-09-10 Genencor International, Inc. Modified forms of pullulanase
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6008335A (en) * 1994-02-11 1999-12-28 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and Crohn's disease
US6013471A (en) * 1994-05-10 2000-01-11 Hybritech Incorporated DNA encoding hK2 variant polypeptides
WO2000015824A1 (en) 1998-09-13 2000-03-23 Karolinska Innovations Ab Transfer method for specific cellular localisation of nucleic acids
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6060260A (en) * 1998-02-27 2000-05-09 Dade Behring Inc. Methods for reducing adsorption in an assay
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6127338A (en) * 1997-04-01 2000-10-03 Calyx Therapeutics, Inc. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6129917A (en) * 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
WO2000073451A1 (en) 1999-06-01 2000-12-07 Schering Corporation Mammalian receptor proteins; related reagents and methods
US6180411B1 (en) 1997-08-01 2001-01-30 The Regents Of The University Of California Light-triggered indicators that memorize analyte concentrations
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
US6207153B1 (en) 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6228638B1 (en) 1997-07-11 2001-05-08 University Of North Texas, Health Science Center At Fort Worth Escherichia coli CSRB gene and RNA encoded thereby
US6235486B1 (en) 1997-06-20 2001-05-22 Mayo Foundation For Medical Education & Research Method for detection of breast cancer
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
WO2001062271A1 (en) 2000-02-22 2001-08-30 The Board Of Trustees Of The University Of Arkansas Compositions and methods for the early diagnosis of ovarian cancer
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
US6294334B1 (en) 1996-11-15 2001-09-25 Board Of Regents, The University Of Texas System Genetic test for equine severe combined immunodeficiency disease
WO2001075078A1 (en) 2000-03-31 2001-10-11 The Scripps Research Institute HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US6303344B1 (en) 1996-12-18 2001-10-16 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6312901B2 (en) 1996-07-08 2001-11-06 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
US20020055617A1 (en) * 1993-06-18 2002-05-09 Marilyn H. Perrin Cloning and recombinant production of cfr receptor(s)
US20020061580A1 (en) * 1997-11-20 2002-05-23 Estell David A. Alpha/beta hydrolase-fold enzymes
WO2002044736A2 (en) 2000-11-30 2002-06-06 Molecular Skincare Limited Diagnosis and treatment of epidermal or skin diseases
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6410687B1 (en) 1998-04-14 2002-06-25 The Regents Of The University Of California Polypeptides for the detection of microtubule depolymerization inhibitors
US20020106661A1 (en) * 1996-07-08 2002-08-08 Burstein Laboratories, Inc. Optical disk-based assay devices and methods
US6433155B1 (en) 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20020110860A1 (en) * 2000-09-18 2002-08-15 Sierd Bron Twin-arginine translocation in Bacillus
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
US20020127641A1 (en) * 1997-09-15 2002-09-12 Estell David A. Proteases from gram-positive organisms
US20020137681A1 (en) * 1999-07-06 2002-09-26 Lawrence Steinman Treatment of demyelinating autoimmune disease with ordered peptides
US6458557B1 (en) 1997-11-20 2002-10-01 Genencor International, Inc. Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US20020154615A1 (en) * 2000-01-28 2002-10-24 Martin Hans Detection method and device
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6482389B1 (en) 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
US20020172980A1 (en) * 2000-11-27 2002-11-21 Phan Brigitte Chau Methods for decreasing non-specific binding of beads in dual bead assays including related optical biodiscs and disc drive systems
US20020187471A1 (en) * 1996-10-01 2002-12-12 Cech Thomas R. Novel telomerase
US20020187467A1 (en) * 1998-04-03 2002-12-12 Thomas Gingeras Mycobacterial rpob sequences
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US20020192839A1 (en) * 1998-03-30 2002-12-19 Epitope, Inc. Collection device for single step assay of oral fluids
US20030003464A1 (en) * 2000-11-27 2003-01-02 Phan Brigitte C. Dual bead assays including optical biodiscs and methods relating thereto
US6506579B1 (en) 1997-07-15 2003-01-14 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms using SecG
US6506553B1 (en) 1995-03-30 2003-01-14 Ortho Diagnostics Systems, Inc. Method for diagnosis of Epstein-Barr virus associated disease
US6521421B1 (en) 1997-07-16 2003-02-18 Genencor International, Inc. Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US6521440B1 (en) 1997-09-15 2003-02-18 Genencor International, Inc. Proteases from gram-positive organisms
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030049254A1 (en) * 2001-06-05 2003-03-13 Kaufman Daniel L. Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule
US20030054446A1 (en) * 2000-11-29 2003-03-20 Weber Bernard H. F. Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US20030064364A1 (en) * 1996-01-23 2003-04-03 Lockhart David J. Nucleic acid analysis techniques
US20030064058A1 (en) * 2001-09-07 2003-04-03 Nadir Askenasy Methods of utilizing bone marrow stem cells for inducing immunological tolerance
US6544792B1 (en) 1999-12-21 2003-04-08 Genencor International, Inc. Production of secreted polypeptides
WO2003030835A2 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
US20030073248A1 (en) * 2001-09-28 2003-04-17 J.W. Roth Bovine pregnancy test
US20030078177A1 (en) * 1997-12-30 2003-04-24 Estell David A. Proteases from gram positive organisms
US20030082596A1 (en) * 2001-08-08 2003-05-01 Michael Mittmann Methods of genetic analysis of probes: test3
US20030086914A1 (en) * 1999-06-25 2003-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and device for inducing biological processes by micro-organs
WO2003043524A2 (en) 2001-11-20 2003-05-30 The Curators Of The University Of Missouri Compositions and methods for accurate early pregnancy diagnosis
US20030104355A1 (en) * 2001-11-02 2003-06-05 Caili Wang Adapter-directed display systems
US20030105770A1 (en) * 2001-11-26 2003-06-05 Macleod Stewart Extending a directory schema independent of schema modification
US20030104410A1 (en) * 2001-03-16 2003-06-05 Affymetrix, Inc. Human microarray
US20030104491A1 (en) * 2000-04-30 2003-06-05 Cabantchik Ioav Zvi Molecules and methods using same for measuring non-transferrin bound iron
US20030108927A1 (en) * 2000-04-03 2003-06-12 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030118593A1 (en) * 1997-07-08 2003-06-26 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
US6599731B1 (en) 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US20030158133A1 (en) * 2001-08-01 2003-08-21 Movsesian Matthew A. Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US20030157642A1 (en) * 1997-07-15 2003-08-21 Caldwell Robert M. Increasing production of proteins in gram-positive microorganisms
US20030158070A1 (en) * 1997-07-15 2003-08-21 Estell David A. Proteases from gram-positive organisms
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
WO2003072799A2 (en) 2002-02-22 2003-09-04 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Brother of the regulator of imprinted sites (boris)
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030180757A1 (en) * 1996-01-23 2003-09-25 Affymetrix, Inc. Nucleic acid labeling compounds
US6630328B2 (en) 1909-07-15 2003-10-07 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms
US20030211556A1 (en) * 2002-01-16 2003-11-13 Fatemi S. Hossein Marker for psychiatric conditions
US20030211490A1 (en) * 2000-01-24 2003-11-13 Hanan Stein Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20030220475A1 (en) * 2001-04-03 2003-11-27 Fields Howard A. Neutralizing immunogenic hev polypepetides
US20030222908A1 (en) * 2002-06-03 2003-12-04 Microsoft Corporation Dynamic wizard interface system and method
WO2003101386A2 (en) 2002-05-30 2003-12-11 Memorial Sloan-Kettering Cancer Center Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
US20030232979A1 (en) * 1998-07-31 2003-12-18 Mcgall Glenn Nucleic acid labeling compounds
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US20040009164A1 (en) * 2002-05-01 2004-01-15 Jonathan Reeves PSP94 diagnostic reagents and assays
US20040013665A1 (en) * 1993-09-15 2004-01-22 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US20040038237A1 (en) * 2001-12-19 2004-02-26 Goldberg Steven L. Pichia pastoris formate dehydrogenase and uses therefor
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20040052769A1 (en) * 2000-11-30 2004-03-18 Yair Reisner Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
WO2004037251A1 (en) 2002-10-24 2004-05-06 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
US20040091946A1 (en) * 2000-11-03 2004-05-13 Oakley Robert H. Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity
US20040101892A1 (en) * 1996-01-23 2004-05-27 Affymetrix, Inc. Nucleic acid labeling compounds
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
US20040126868A1 (en) * 1997-07-15 2004-07-01 Estell David A. Gram-positive microorganisms with an inactivated cysteine protease-3
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US20040132109A1 (en) * 2001-01-23 2004-07-08 Masato Enari Method
WO2004060135A2 (en) 2003-01-02 2004-07-22 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US6770449B2 (en) 1997-06-05 2004-08-03 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6794179B2 (en) 1997-12-30 2004-09-21 Genencor International, Inc. Proteases from gram positive organisms
US20040186280A1 (en) * 2002-12-19 2004-09-23 Murdoch University BmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof
US20040197334A1 (en) * 2003-04-02 2004-10-07 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040209246A1 (en) * 2003-04-15 2004-10-21 Agouron Pharmaceuticals, Inc. Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
US20040210045A1 (en) * 1996-01-23 2004-10-21 Mcgall Glenn Nucleic acid labeling compounds
US20040214248A1 (en) * 2001-04-06 2004-10-28 Roberts David D Use of semenogelin in the diagnosis, prognosis and treatment of cancer
WO2004096157A2 (en) 2003-03-07 2004-11-11 New England Medical Center Hospitals, Inc. Treatment of igai deposition diseases
US20040229245A1 (en) * 2003-01-06 2004-11-18 Anton Bittner Methods and algorithms for performing quality control during gene expression profiling on DNA microarray technology
US20040242529A1 (en) * 1997-04-18 2004-12-02 Geron Corporation Vector encoding inactivated telomerase for treating cancer
US20040248093A1 (en) * 2000-11-27 2004-12-09 Coombs James Howard Magneto-optical bio-discs and systems including related methods
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US20050022269A1 (en) * 2001-07-19 2005-01-27 Joseph Hirschberg Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050031618A1 (en) * 2001-01-31 2005-02-10 Dror Mevorach Induction of tolerance by apoptotic and/or necrotic cells
US20050032126A1 (en) * 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
WO2005016282A2 (en) 2003-08-14 2005-02-24 Exelixis, Inc. Prkcs as modifiers of the beta catenin pathway and methods of use
WO2005019409A2 (en) 2002-07-15 2005-03-03 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050064435A1 (en) * 2003-09-24 2005-03-24 Xing Su Programmable molecular barcodes
US20050064479A1 (en) * 2003-08-12 2005-03-24 Affymetrix, Inc. Compounds and methods for post incorporation labeling of nucleic acids
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
WO2005033142A2 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Anti-nik antibodies and uses thereof
WO2005033145A1 (en) 2003-10-07 2005-04-14 Yeda Research And Development Co. Ltd. Antibodies to nik, their preparation and use
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US20050106623A1 (en) * 2000-11-03 2005-05-19 Oakley Robert H. Modified G-protein coupled receptors
US20050113327A1 (en) * 1999-08-30 2005-05-26 Levava Roiz Methods of and compositions for inhibiting the proliferation of mammalian cells
WO2005051423A2 (en) 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
US20050136431A1 (en) * 2000-11-03 2005-06-23 Oakley Robert H. Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050152912A1 (en) * 2003-03-26 2005-07-14 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822A1 (en) * 2004-01-20 2005-07-21 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
US6924094B1 (en) 1996-02-08 2005-08-02 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US20050176137A1 (en) * 1999-02-04 2005-08-11 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity
US20050191285A1 (en) * 1993-03-17 2005-09-01 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20050202098A1 (en) * 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US20050220774A1 (en) * 2002-03-18 2005-10-06 Tony Peled Methods of inducing differentiation in ex vivo expanded stem cells
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20050249789A1 (en) * 1997-11-20 2005-11-10 Estell David A Alpha/beta hydrolase-fold enzymes
US6965020B2 (en) 1996-01-23 2005-11-15 Affymetrix, Inc. Nucleic acid labeling compounds
US20050255101A1 (en) * 2002-02-13 2005-11-17 Technion Research And Development Foundation Ltd. Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643A1 (en) * 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
US20050271655A1 (en) * 2002-08-10 2005-12-08 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2005118864A2 (en) 2004-05-28 2005-12-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US20050281916A1 (en) * 2001-05-18 2005-12-22 Kirsten Bojsen Method of improving dough and bread quality
US20050287604A1 (en) * 2002-05-31 2005-12-29 Bohmer Ralph M Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
US20050287563A1 (en) * 1996-01-23 2005-12-29 Affymetrix, Inc. Nucleic acid labeling compounds
US20060002135A1 (en) * 2004-07-01 2006-01-05 Eurodent S.P.A. Dental lamp particularly for medical and dental surgeries
US20060008479A1 (en) * 1996-04-01 2006-01-12 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US20060019340A1 (en) * 1999-06-08 2006-01-26 David Naor CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060029984A1 (en) * 2002-05-01 2006-02-09 Jonathan Reeves PSP94 diagnostic reagents and assays
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20060035980A1 (en) * 2003-04-18 2006-02-16 Scanlan Thomas S Thyronamine derivatives and analogs and methods of use thereof
US20060035367A1 (en) * 1997-12-30 2006-02-16 Estell David A Proteases from gram positive organisms
US20060040307A1 (en) * 1997-04-18 2006-02-23 Geron Corporation Human telomerase catalytic subunit
US20060039897A1 (en) * 2002-03-26 2006-02-23 Tamar Lotan Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060051426A1 (en) * 2001-12-05 2006-03-09 Gershon Golomb Nanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
WO2006024694A2 (en) 2004-09-03 2006-03-09 Licentia Oy Peptide inhibitors of hk2 and their use
WO2006034048A2 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20060078951A1 (en) * 2004-10-08 2006-04-13 Youn Byung S Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US20060079941A1 (en) * 2004-10-12 2006-04-13 Eli Ovsyshcher Methods and implantable devices for treating supraventricular arrhythmias
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2006043178A2 (en) 2004-10-18 2006-04-27 Danisco A/S Enzymes
EP1655381A1 (en) 2004-11-04 2006-05-10 Affymetrix, Inc. (A US Entity) Nucleic acid labeling methods
US20060099273A1 (en) * 2000-09-28 2006-05-11 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060105354A1 (en) * 2004-11-18 2006-05-18 Eppendorf Array Technologies S.A. Real-time quantification of multiple targets on a micro-array
US7053268B1 (en) 1999-06-17 2006-05-30 Danisco A/S Promoter
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US20060123516A1 (en) * 2003-05-22 2006-06-08 Gil Ronen Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7060283B1 (en) 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
US20060134538A1 (en) * 2004-12-16 2006-06-22 Radu Nora S Aromatic chalcogen compounds and their use
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060140934A1 (en) * 2004-09-24 2006-06-29 Colin Gegg Modified Fc molecules
US20060148078A1 (en) * 2002-11-29 2006-07-06 Sharon Gerecht-Nir Method of dynamically culturing embryonic stem cells
US20060159769A1 (en) * 2000-09-28 2006-07-20 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1683874A2 (en) 2000-08-29 2006-07-26 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
US20060188944A1 (en) * 1997-06-05 2006-08-24 Barak Lawrence S Methods of assaying receptor activity
WO2006090388A2 (en) 2005-02-25 2006-08-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Fruit cell culture extract for treating inflammation
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US20060198817A1 (en) * 2002-11-26 2006-09-07 Alverdy John C Materials and methods for preventing and treating microbe-mediated epithelial disorders
US20060211064A1 (en) * 2005-03-18 2006-09-21 Hyesook Kim Detection of hypertension using glucuronidated metabolic products
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2006107962A2 (en) 2005-04-04 2006-10-12 Biogen Idec Ma Inc Methods and products for evaluating an immune response to a therapeutic protein
US20060234947A1 (en) * 2002-01-31 2006-10-19 Tel Aviv University Future Technology Development L.P Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060234203A1 (en) * 2005-04-19 2006-10-19 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060257429A1 (en) * 2003-10-23 2006-11-16 Dreier Kimberly J Vaccine for periodontal disease
US20060260002A1 (en) * 2003-06-19 2006-11-16 Gil Ronen Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20060263828A1 (en) * 2003-01-24 2006-11-23 Sudha Shenoy Modified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera
EP1728875A2 (en) 1996-02-08 2006-12-06 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US20060275267A1 (en) * 1998-03-31 2006-12-07 Morin Gregg B Nucleic acids encoding inactive variants of human telomerase
US20060281106A1 (en) * 1997-10-01 2006-12-14 Andrews William H Telomerase promoter sequences for screening telomerase modulators
WO2006134602A2 (en) 2005-06-16 2006-12-21 Ramot At Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US20060292579A1 (en) * 1994-10-21 2006-12-28 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
WO2007001986A2 (en) 2005-06-20 2007-01-04 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20070026106A1 (en) * 2003-01-17 2007-02-01 Kreij Arno D Method
US20070032421A1 (en) * 2003-12-12 2007-02-08 Efrat Levy Methods and compositions relating to cystatin C
US20070037187A1 (en) * 2000-03-24 2007-02-15 Isabelle Alexandre Identification and quantification of a plurality of biological (micro)organisms or their components
WO2007020638A2 (en) 2005-08-15 2007-02-22 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A2 (en) 2005-08-24 2007-03-01 Yeda Research And Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007027714A2 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
EP1762243A1 (en) 1999-03-31 2007-03-14 Oxford Biomedica (UK) Ltd Factor for regulation of neurite growth
US20070059717A1 (en) * 2005-09-15 2007-03-15 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
US7192555B2 (en) 1998-03-30 2007-03-20 Orasure Technologies, Inc. Device for collection and assay of oral fluids
WO2007031996A1 (en) 2005-09-12 2007-03-22 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US20070065429A1 (en) * 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
WO2007034487A1 (en) 2005-09-22 2007-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070071751A1 (en) * 1996-09-24 2007-03-29 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US20070099204A1 (en) * 2000-03-24 2007-05-03 Isabelle Alexandre Identification and quantification of a plurality of biological (micro)organisms or their components
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
US7223902B1 (en) 1999-11-19 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US20070134658A1 (en) * 2003-03-05 2007-06-14 Genetic Technologies Limited, A.C.N. 009 212 328 Identification of fetal dna and fetal cell markers in maternal plasma or serum
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
EP1798287A2 (en) 1997-08-01 2007-06-20 Schering Corporation Mammalian cell membrane proteins and related reagents
US20070141658A1 (en) * 2005-10-27 2007-06-21 The Regents Of The University Of California Fluorogenic probes for reactive oxygen species
EP1803816A2 (en) 1996-12-13 2007-07-04 Schering Corporation Mammalian cell surface antigens; related reagents
US20070161007A1 (en) * 2006-01-11 2007-07-12 Wisconsin Alumni Research Foundation Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use
US20070160546A1 (en) * 2000-09-28 2007-07-12 Tamar Lotan Use of stinging cells/capsules for the delivery of active agents to keratinous substances
EP1810978A2 (en) 2000-08-08 2007-07-25 St. Jude Children's Research Hospital Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof
US20070178462A1 (en) * 2004-02-18 2007-08-02 Uebele Victor N Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US20070184530A1 (en) * 2006-02-03 2007-08-09 Fuad Fares Long-acting veterinary polypeptides and methods of producing and administering same
WO2007088051A2 (en) 2006-01-31 2007-08-09 Bayer Schering Pharma Aktiengesellschaft Modulation of mdl-1 activity for treatment of inflammatory disease
US20070190534A1 (en) * 2001-06-11 2007-08-16 Genesis Genomics Inc. Mitochondrial sites and genes associated with prostate cancer
WO2007091254A1 (en) 2006-02-06 2007-08-16 Rappaport Family Institute For Research In The Medical Sciences Methods and kit for diagnosing t1dm
US20070196369A1 (en) * 2002-02-20 2007-08-23 Hoogenboom Henricus Renerus J MHC-peptide complex binding ligands
US7262288B1 (en) 1997-04-18 2007-08-28 Geron Corporation Nucleic acids encoding human telomerase reverse transcriptase and related homologs
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US7270810B2 (en) 2000-01-05 2007-09-18 Yeda Research And Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070218511A1 (en) * 1998-03-31 2007-09-20 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
WO2007110869A2 (en) 2006-03-28 2007-10-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to warfarin resistance
US7291463B2 (en) 1996-01-23 2007-11-06 Affymetrix, Inc. Nucleic acid labeling compounds
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
WO2008010934A2 (en) 2006-07-14 2008-01-24 Chemocentryx, Inc. Triazolyl phenyl benzenesulfonamides
WO2008010228A2 (en) 2006-07-20 2008-01-24 Yeda Research And Development Co. Ltd. Photosyntheticorganisms and compositions and methods of generating same
US20080026394A1 (en) * 2006-07-11 2008-01-31 Antara Biosciences Inc. Methods of detecting one or more cancer markers
US20080044416A1 (en) * 1999-02-09 2008-02-21 Gang An Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2008026198A2 (en) 2006-08-28 2008-03-06 Yeda Research And Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
EP1897949A2 (en) 1998-09-21 2008-03-12 Schering Corporation Human interleukin-B50. Therapeutic uses
US20080064114A1 (en) * 2006-09-07 2008-03-13 Institut Pasteur Genomic morse code
EP1903107A1 (en) 1999-09-24 2008-03-26 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US20080075322A1 (en) * 2006-09-13 2008-03-27 Fluidigm Corporation Methods and systems for determining a baseline during image processing
US20080075380A1 (en) * 2006-09-13 2008-03-27 Fluidigm Corporation Methods and systems for image processing of microfluidic devices
EP1905832A2 (en) 1999-09-09 2008-04-02 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
US20080082678A1 (en) * 2005-01-16 2008-04-03 Zlango Ltd. Communications Network System and Methods for Using Same
EP1908837A2 (en) 2000-05-25 2008-04-09 Schering Corporation Human receptor proteins, related reagents and methods
WO2008041183A2 (en) 2006-10-05 2008-04-10 Technion Research & Development Foundation Ltd. Microtubes and methods of producing same
US20080085526A1 (en) * 2006-09-08 2008-04-10 United Therapeutics Corporation Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
WO2008043566A2 (en) 2006-10-11 2008-04-17 Janssen Pharmaceutica N.V. Compositions and methods for treating and diagnosing irritable bowel syndrome
WO2008051761A2 (en) 2006-10-26 2008-05-02 Abbott Laboratories Assay for cardiac troponin autoantibodies
EP1918377A1 (en) 2000-05-10 2008-05-07 Schering Corporation Mammalian cytokine receptor subunit proteins, related reagents and methods
US20080131419A1 (en) * 2004-09-29 2008-06-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant Human T2 Rnase and Uses Thereof
WO2008067547A2 (en) 2006-11-30 2008-06-05 Research Development Foundation Improved immunoglobulin libraries
US20080129736A1 (en) * 2006-11-30 2008-06-05 Fluidigm Corporation Method and apparatus for biological sample analysis
US20080138346A1 (en) * 1994-12-07 2008-06-12 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
WO2008076321A1 (en) 2006-12-14 2008-06-26 Schering Corporation Engineered anti-tslp antibody
EP1942114A2 (en) 1999-03-11 2008-07-09 Schering Corporation Mammalian cytokines; related reagents and methods
EP1947183A1 (en) 1996-08-16 2008-07-23 Schering Corporation Mammalian cell surface antigens; related reagents
DE212006000071U1 (en) 2005-11-18 2008-07-24 Board of Regents, The University of Texas System, Austin Quantification of fusion proteins and their activity as a result of chromosomal translocation
WO2008092164A2 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008093342A2 (en) 2007-02-01 2008-08-07 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
WO2008093341A2 (en) 2007-01-31 2008-08-07 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
US20080199895A1 (en) * 2006-10-05 2008-08-21 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080206188A1 (en) * 2004-04-20 2008-08-28 Alverdy John C Therapeutic Delivery System Comprising a High Molecular Weight Peg-Like Compound
EP1964921A2 (en) 2000-04-05 2008-09-03 Oscient Pharmaceuticals Corporation The high bone mass gene of 11q13.3
US20080214407A1 (en) * 2006-10-12 2008-09-04 Eppendorf Array Technologies S.A. Method and system for quantification of a target compound obtained from a biological sample upon chips
JP2008203195A (en) * 2007-02-22 2008-09-04 Japan Science & Technology Agency Bsh immunoassay kit and bsh measuring method
US20080219995A1 (en) * 2007-02-16 2008-09-11 Konkuk University Industrial Cooperation Corp. Il-32 monoclonal antibodies and uses thereof
US20080220498A1 (en) * 2007-03-06 2008-09-11 Cervin Marguerite A Variant Buttiauxella sp. phytases having altered properties
WO2008110006A1 (en) 2007-03-12 2008-09-18 Miraculins Inc. Biomarkers of prostate cancer and uses thereof
EP1975231A1 (en) 2002-01-22 2008-10-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
WO2008120202A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A1 (en) 2007-04-02 2008-10-09 Ramot At Tel Aviv University Ltd. Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
EP1980573A2 (en) 1997-07-09 2008-10-15 Schering Corporation Isolated dendritic cell membrane protein genes
WO2008124670A2 (en) 2007-04-06 2008-10-16 Becton, Dickinson And Company Compositions and methods for the identification of a carbapenemase gene
EP1983001A2 (en) 1998-09-25 2008-10-22 Schering Corporation Antibodies to mammalian Langerhans cell antigen and their uses
US7442781B2 (en) 2001-08-16 2008-10-28 Urifer Ltd. Diagnosis, prevention and treatment of cancer
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
US20080274905A1 (en) * 2005-09-30 2008-11-06 The Trustees Of Columbia University In The City Of New York Microfluidic cells with parallel arrays of individual dna molecules
WO2008132753A2 (en) 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for detecting fetal cells in the maternal blood
EP1990057A1 (en) 2001-05-22 2008-11-12 Merck & Co., Inc. Beta-secretase substrates and uses thereof
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
US20080287667A1 (en) * 2001-03-12 2008-11-20 Affymetrix, Inc. Nucleic Acid Labeling Compounds
US20080299084A1 (en) * 2004-08-26 2008-12-04 Engeneic Therapy Pty. Ltd. Bacterially derived intact minicells that encompass plasma free functional nucleic acid for in vivo delivery to mammalian cells
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US20090005410A1 (en) * 2007-06-22 2009-01-01 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl) hetaryl arylsulfonamides
US20090013087A1 (en) * 2005-01-18 2009-01-08 Zlango Ltd. Communications Network System and Methods For Using Same
US20090023594A1 (en) * 2006-11-29 2009-01-22 Exiqon A/S Reagents for labelling nucleic acids and uses thereof
WO2009010968A2 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2020239A1 (en) 2000-04-18 2009-02-04 Schering Corporation Use of IL-174 agonists for treating infectious diseases
US20090036321A1 (en) * 2003-06-03 2009-02-05 Chiron Corporation Methods for predicting the course of a malignant disease
US20090035784A1 (en) * 2004-07-30 2009-02-05 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof
WO2009021054A2 (en) 2007-08-06 2009-02-12 Orion Genomics Llc Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
US20090042209A1 (en) * 2006-09-01 2009-02-12 Nox Technologies, Inc. Neoplasia-Specific tNOX Isoforms and Methods
EP2026070A1 (en) 2002-09-09 2009-02-18 Arbor Vita Corporation Methods of diagnosing cervical cancer
EP2028187A1 (en) 2000-09-08 2009-02-25 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
US20090053224A1 (en) * 2007-08-02 2009-02-26 Arresto Biosciences Lox and loxl2 inhibitors and uses thereof
EP2031070A1 (en) 2002-12-04 2009-03-04 Applera Corporation Multiplex amplification of polynucleotides
US20090068669A1 (en) * 2007-09-12 2009-03-12 Elias Georges Slc9a3r1 directed diagnostics for neoplastic disease
WO2009032477A2 (en) 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
WO2009034574A2 (en) 2007-09-12 2009-03-19 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
EP2042869A2 (en) 1999-12-06 2009-04-01 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US20090098249A1 (en) * 2007-02-07 2009-04-16 Cervin Marguerite A Variant Buttiauxella sp. Phytases having altered properties
US20090104170A1 (en) * 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
EP2058275A1 (en) 2003-01-07 2009-05-13 Ramot at Tel-Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2058333A2 (en) 1998-07-23 2009-05-13 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US20090123553A1 (en) * 2002-12-09 2009-05-14 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US20090126042A1 (en) * 2004-06-14 2009-05-14 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090136916A1 (en) * 2007-08-13 2009-05-28 Trustees Of Tufts College Methods and microarrays for detecting enteric viruses
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US20090143243A1 (en) * 2007-08-12 2009-06-04 Gunning Kerry B Microarray system with improved sequence specificity
US20090143321A1 (en) * 2005-07-07 2009-06-04 Avraham Hochberg Nucleic acid agents for downregulating h19 and methods of using same
EP2070944A1 (en) 2001-10-11 2009-06-17 Amgen Inc. Specific binding agents of human angiopoietin-2
EP2071021A2 (en) 2007-12-12 2009-06-17 University of South Florida Bone marrow-derived neuronal cells
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US20090170072A1 (en) * 1999-03-29 2009-07-02 Orasure Technologies, Inc. Device for collection and assay of oral fluids
EP2077277A1 (en) 2002-02-01 2009-07-08 Schering Corporation Use of mammalian cytokine; related reagents
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
WO2009083958A2 (en) 2007-12-27 2009-07-09 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
EP2080766A1 (en) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides useful for immunomodulation
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US20090208533A1 (en) * 2004-08-11 2009-08-20 University Of Georgia Research Foundation, Inc. Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
WO2009104174A2 (en) 2008-02-21 2009-08-27 Technion Research & Development Foundation Ltd . A method of attaching a cell-of-interest to a microtube
WO2009105833A1 (en) 2008-02-28 2009-09-03 Murdoch University Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US20090221015A1 (en) * 2006-05-09 2009-09-03 Spinale Francis G Detecting Diastolic Heart Failure by Protease and Protease Inhibitor Plasma Profiling
US20090226387A1 (en) * 2005-12-23 2009-09-10 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
EP2100959A2 (en) 1997-07-25 2009-09-16 Schering Corporation Mammalian cytokine: interleukin-B30 and related reagents
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US20090233946A1 (en) * 2007-07-12 2009-09-17 Antoni Krasinski Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation
WO2009117773A1 (en) 2008-03-27 2009-10-01 Murdoch University Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US20090246800A1 (en) * 2006-10-26 2009-10-01 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
EP2107125A1 (en) 2008-03-31 2009-10-07 Eppendorf Array Technologies SA (EAT) Real-time PCR of targets on a micro-array
US20090253170A1 (en) * 2003-06-19 2009-10-08 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
WO2009132124A2 (en) 2008-04-24 2009-10-29 The Trustees Of Columbia University In The City Of New York Geometric patterns and lipid bilayers for dna molecule organization and uses thereof
US20090269780A1 (en) * 2008-04-23 2009-10-29 Luminex Corporation Method for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2119771A2 (en) 2003-12-24 2009-11-18 Danisco A/S Proteins
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20090293146A1 (en) * 2006-12-20 2009-11-26 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
EP2128270A1 (en) 2003-08-08 2009-12-02 Genenews Inc. Osteoarthritis biomarkers and uses thereof
EP2131198A2 (en) 2001-09-20 2009-12-09 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US20090311695A1 (en) * 2008-03-12 2009-12-17 Talat Nasim Method
EP2135619A1 (en) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
EP2138510A1 (en) 1999-07-30 2009-12-30 Schering Corporation Methods of generating antibodies against cytokines
US20090324612A1 (en) * 2001-06-05 2009-12-31 Kaufman Daniel L Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US20100004162A1 (en) * 1998-09-18 2010-01-07 Nathaniel Heintz Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US20100015651A1 (en) * 2006-07-11 2010-01-21 Musc Foundation For Research Development Predicting Heart Failure Following Myocardial Infarction by Protease and Protease Inhibitor Profiling
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US7655225B2 (en) 2002-01-25 2010-02-02 Gamida Cell, Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
WO2010016806A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
WO2010017544A2 (en) 2008-08-08 2010-02-11 Genisphere, Inc. Long-acting dna dendrimers and methods thereof
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US20100047230A1 (en) * 2005-02-21 2010-02-25 Hellenic Pasteur Institute Anti her2/neu antibody
US20100055033A1 (en) * 2006-04-07 2010-03-04 The Government Of The United States Of America As Represented By The Secretary Antibody compositions and methods for treatment of neoplastic disease
US20100062501A1 (en) * 2003-12-24 2010-03-11 Paul Wassell Method
US20100062947A1 (en) * 2007-01-11 2010-03-11 Erasmus University Medical Center Circular chromosome conformation capture (4c)
WO2010031006A1 (en) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
WO2010029545A2 (en) 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s. pneumoniae infection
US20100068135A1 (en) * 2005-08-08 2010-03-18 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
WO2010035261A2 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US20100081177A1 (en) * 2008-09-05 2010-04-01 TransAlgae Ltd Decreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
EP2172478A2 (en) 1997-02-07 2010-04-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor III (ADNF III)
EP2174668A2 (en) 2004-11-14 2010-04-14 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100092386A1 (en) * 2007-04-23 2010-04-15 David Segev System for delivering therapeutic agents into living cells and cells nuclei
WO2010040277A1 (en) 2008-10-09 2010-04-15 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2177503A1 (en) 2004-02-20 2010-04-21 UCL Business PLC Modulators of cannabinoid receptors
US20100105608A1 (en) * 2002-01-31 2010-04-29 Tel Aviv University Future Technology Development L.P. Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105759A1 (en) * 2007-01-16 2010-04-29 Abraham Hochberg H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100105071A1 (en) * 2007-02-28 2010-04-29 Children's Medical Center Corporation Methods for predicting the onset of menarche
EP2182052A1 (en) 2002-10-07 2010-05-05 Technion Research and Development Foundation, Ltd. Human foreskin cells suitable for culturing stem cells
WO2010049897A2 (en) 2008-10-30 2010-05-06 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010054328A2 (en) 2008-11-07 2010-05-14 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
EP2186530A1 (en) 2000-11-17 2010-05-19 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2010055525A1 (en) 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Method for predicting a patient's responsiveness to anti-folate therapy
US20100129346A1 (en) * 2006-08-22 2010-05-27 G2 Inflammation Pty Ltd. Anti-C5aR Antibodies With Improved Properties
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
WO2010064247A1 (en) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010068757A1 (en) 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010066252A1 (en) 2008-12-09 2010-06-17 Dako Denmark A/S Method for evaluating pre-treatment
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2202240A1 (en) 2000-08-18 2010-06-30 Sterix Limited Compound
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076756A2 (en) 2008-12-29 2010-07-08 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076642A1 (en) 2008-12-29 2010-07-08 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
EP2208797A2 (en) 2004-03-01 2010-07-21 Applied Biosystems, LLC Methods, compositions and kits for use in polynucleotide amplification
US20100184065A1 (en) * 2007-07-10 2010-07-22 University Of South Florida Method of Predicting Non-Response to First Line Chemotherapy
EP2210899A1 (en) 2004-11-11 2010-07-28 Danisco A/S pntr transcription factor
US20100190662A1 (en) * 2007-01-26 2010-07-29 Rebecca Sutphen Methods and materials for detection, diagnosis and management of ovarian cancer
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010086856A2 (en) 2009-02-01 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
US20100196419A1 (en) * 2007-05-02 2010-08-05 Compans Richard W Enhancement of glycoprotein incorporation into virus-like particles
EP2216033A2 (en) 2003-03-06 2010-08-11 Yeda Research and Development Co. Ltd. Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010093450A2 (en) 2009-02-11 2010-08-19 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093820A2 (en) 2009-02-11 2010-08-19 Orion Genomics Llc Combinations of polymorphisms for determining allele-specific expression of igf2
WO2010096658A1 (en) 2009-02-19 2010-08-26 The Cleveland Clinic Foundation Corin as a marker for heart failure
WO2010096434A2 (en) 2009-02-18 2010-08-26 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100215803A1 (en) * 2007-08-17 2010-08-26 Niels Erik Larsen Process
EP2224008A2 (en) 2005-05-12 2010-09-01 Murdoch University Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
WO2010097794A1 (en) 2009-02-26 2010-09-02 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of reprogramming renal cells
US20100221272A1 (en) * 2007-06-28 2010-09-02 University Of Saskatchewan Immunomodulatory compositions and methods for treating disease with modified host defense peptides
WO2010100595A2 (en) 2009-03-02 2010-09-10 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
US20100240065A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Prolyl Hydroxylase Compositions and Methods of Use Thereof
US20100240101A1 (en) * 2009-03-19 2010-09-23 Massachusetts Institute Of Technology Parallel Proximity Ligation Event Analysis
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
WO2010113146A1 (en) 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
WO2010115261A1 (en) 2009-03-27 2010-10-14 Genesis Genomics Inc. Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor
EP2246444A1 (en) 2004-09-14 2010-11-03 The Regents of the University of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
WO2010126670A2 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US20100291602A1 (en) * 2009-05-14 2010-11-18 University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
WO2010134035A1 (en) 2009-05-19 2010-11-25 Danisco A/S Use
EP2256203A1 (en) 2003-11-21 2010-12-01 Schering Corporation IL-23 and its receptor; related reagents and methods
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
WO2010137020A1 (en) 2009-05-28 2010-12-02 Yeda Research And Development Co. Ltd. Methods of treating inflammation
WO2010137017A2 (en) 2009-05-27 2010-12-02 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
WO2010141421A1 (en) 2009-06-02 2010-12-09 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
EP2261256A2 (en) 1999-11-24 2010-12-15 Schering Corporation Methods of inhibiting metastasis
US7855075B2 (en) 1998-02-17 2010-12-21 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
EP2267108A1 (en) 2004-07-16 2010-12-29 Danisco A/S Enzymatic oil-degumming method
EP2266624A2 (en) 2002-07-15 2010-12-29 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
WO2010150259A1 (en) 2009-06-24 2010-12-29 Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical Center Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2010150213A1 (en) 2009-06-25 2010-12-29 Danisco A/S Protein
EP2266405A2 (en) 2004-03-12 2010-12-29 Danisco A/S Fungal lipolytic enzymes
WO2011002834A2 (en) 2009-07-01 2011-01-06 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2272869A2 (en) 2001-10-11 2011-01-12 Amgen Inc. Angiopoietin-2 specific binding agents
WO2011004361A2 (en) 2009-07-09 2011-01-13 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20110009861A1 (en) * 2007-01-04 2011-01-13 Music Foundation For Research Development Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP2275445A2 (en) 2004-03-12 2011-01-19 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2278015A1 (en) 2003-01-17 2011-01-26 Danisco A/S Method of producing a carbohydrate ester
WO2011010309A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
US20110020357A1 (en) * 2008-04-09 2011-01-27 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
EP2280285A1 (en) 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2279726A2 (en) 2005-05-26 2011-02-02 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2011013130A2 (en) 2009-07-31 2011-02-03 Ramot At Tel-Aviv University Ltd. Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
EP2281841A2 (en) 2004-12-03 2011-02-09 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
US20110033473A1 (en) * 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011021194A2 (en) 2009-08-17 2011-02-24 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
WO2011021171A1 (en) 2009-08-21 2011-02-24 Beeologics, Llc Preventing and curing beneficial insect diseases via plant transcribed molecules
EP2289567A2 (en) 2003-12-22 2011-03-02 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
US20110052501A1 (en) * 2008-01-31 2011-03-03 Liat Dassa Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2292661A2 (en) 2003-11-10 2011-03-09 Schering Corporation Interleukin-10 antibodies
EP2292760A2 (en) 2000-11-10 2011-03-09 Schering Corporation Mammalian cytokines, receptors, related reagents and methods
EP2295978A2 (en) 1998-03-20 2011-03-16 The Curators Of The University Of Missouri Early pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
EP2295980A1 (en) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
WO2011030332A2 (en) 2009-09-08 2011-03-17 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
US20110065649A1 (en) * 2006-04-27 2011-03-17 Centre National De La Recherche Scientifique (Cnrs) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
WO2011030336A1 (en) 2009-09-08 2011-03-17 Ramot At Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
EP2298316A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
WO2011033511A1 (en) 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
WO2011033506A2 (en) 2009-09-17 2011-03-24 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2302072A1 (en) 2004-11-18 2011-03-30 Eppendorf Array Technologies S.A. Real time-PCR of targets on a micro-array
WO2011038160A2 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
WO2011038403A1 (en) 2009-09-28 2011-03-31 Yuling Luo Methods of detecting nucleic acid sequences with high specificity
EP2305794A1 (en) 2002-01-24 2011-04-06 Gamida Cell Ltd. Expansion of renewable stem cell populations
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011041319A2 (en) 2009-09-29 2011-04-07 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP2308994A1 (en) 2001-03-23 2011-04-13 Yeda Research And Development Co., Ltd. Methods for determining a risk to develop cancer
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
US20110091454A1 (en) * 2004-01-27 2011-04-21 Alex Diber Methods and systems for annotating biomolecular sequences
WO2011045796A1 (en) 2009-10-14 2011-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
WO2011046570A1 (en) 2009-10-16 2011-04-21 The University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
EP2316441A1 (en) 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
EP2316950A1 (en) 2000-03-27 2011-05-04 Technion Research and Development Foundation, Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319941A2 (en) 2005-10-21 2011-05-11 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
EP2319857A2 (en) 2003-03-04 2011-05-11 Yeda Research And Development Co., Ltd. Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
WO2011055366A1 (en) 2009-11-08 2011-05-12 Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of Israel Mo-1 conditional knock-out non-human animal and uses thereof
WO2011056688A2 (en) 2009-10-27 2011-05-12 Caris Life Sciences, Inc. Molecular profiling for personalized medicine
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
WO2011058557A1 (en) 2009-11-12 2011-05-19 Ramot At Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
US20110117560A1 (en) * 2009-11-17 2011-05-19 Musc Foundation For Research Development ASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS
WO2011061657A1 (en) 2009-11-17 2011-05-26 Danisco A/S Method
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US20110129818A1 (en) * 2009-12-02 2011-06-02 Abbott Laboratories ASSAY FOR CARDIAC TROPONIN-T (cTnT)
US20110130306A1 (en) * 2008-06-10 2011-06-02 The Regents Of The University Of California Pro-fluorescent probes
US20110129854A1 (en) * 2009-12-02 2011-06-02 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
WO2011064669A2 (en) 2009-11-30 2011-06-03 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
WO2011064773A1 (en) 2009-11-24 2011-06-03 Collplant Ltd. Method of generating collagen fibers
US7955814B2 (en) 2003-01-17 2011-06-07 Danisco A/S Method
EP2330132A1 (en) 2003-04-04 2011-06-08 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
WO2011068676A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
US20110136103A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Autoantibody enhanced immunoassays and kits
US7960150B2 (en) 2007-01-25 2011-06-14 Danisco A/S Production of a lipid acyltransferase from transformed Bacillus licheniformis cells
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
EP2336321A1 (en) 1999-05-13 2011-06-22 Medical Research Council Ox2 receptor homolog
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20110147993A1 (en) * 2008-04-10 2011-06-23 Objet Geometries Ltd. System and method for three dimensional model printing
US20110150874A1 (en) * 2006-05-19 2011-06-23 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
EP2338913A1 (en) 1995-12-18 2011-06-29 The University of Utah Research Foundation Chromosome 13-linked breast cancer susceptibility gene
EP2339032A1 (en) 2005-04-18 2011-06-29 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2338896A2 (en) 2002-12-12 2011-06-29 R.B.T. (Rakuto Bio Technologies) Ltd. Use of lignin peroxidase in skin and hair lightening
WO2011076881A1 (en) 2009-12-22 2011-06-30 Arabian Gulf University Mutant ldl receptor gene
US7972638B2 (en) 1998-07-21 2011-07-05 Danisco A/S Foodstuff
EP2341144A1 (en) 1999-01-11 2011-07-06 Schering Corporation Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
EP2341346A2 (en) 2000-10-18 2011-07-06 The Regents of the University of California Methods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
WO2011080740A1 (en) 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
WO2011080674A2 (en) 2009-12-28 2011-07-07 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
US20110172113A1 (en) * 2008-03-28 2011-07-14 Mitomics Inc. Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
US20110171346A1 (en) * 2008-04-18 2011-07-14 Spaangner Christiansen Liv Process
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
WO2011086509A1 (en) 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US20110189677A1 (en) * 2010-02-03 2011-08-04 Massachusetts Institute Of Technology Methods For Preparing Sequencing Libraries
WO2011094669A1 (en) 2010-01-29 2011-08-04 Advanced Cell Diagnostics, Inc. Methods of in situ detection of nucleic acids
US20110190477A1 (en) * 2008-02-20 2011-08-04 Peter Whitfeld Humanized Anti-C5aR Antibodies
WO2011097627A1 (en) 2010-02-08 2011-08-11 Agensys, Inc. Antibody drug conjugates (adc) that bind to 161p2f10b proteins
US20110201559A1 (en) * 2008-05-22 2011-08-18 Centre National De La Recherche Scientifique (Cnrs) New Optically Pure Compounds for Improved Therapeutic Efficiency
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
EP2359853A1 (en) 2000-08-08 2011-08-24 Technion Research and Development Foundation, Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359832A2 (en) 2004-09-18 2011-08-24 University of Maryland, Baltimore Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
US20110207664A1 (en) * 2000-02-25 2011-08-25 Vegenics Pty Limited Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2011104708A2 (en) 2010-02-24 2011-09-01 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
EP2365087A2 (en) 2003-05-22 2011-09-14 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2364994A1 (en) 1994-01-05 2011-09-14 Schering Corporation Purfied primate CTLA-8 antigens and related reagents
WO2011111034A1 (en) 2010-03-08 2011-09-15 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
WO2011111050A2 (en) 2010-03-11 2011-09-15 Jacob Edrei Methods of generating hydrogen
EP2366775A1 (en) 2006-03-23 2011-09-21 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
WO2011114251A1 (en) 2010-03-18 2011-09-22 Danisco A/S Foodstuff
US8030044B2 (en) 2003-12-24 2011-10-04 Danisco A/S Lipid acyltransferases
EP2371955A1 (en) 2002-09-26 2011-10-05 K.U. Leuven Research & Development Integrase cofactor
EP2371861A1 (en) 2002-01-25 2011-10-05 G2 Therapies Limited Monoclonal antibodies against extracellular loops of C5aR
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A1 (en) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A2 (en) 2010-04-28 2011-11-03 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP2385124A2 (en) 1999-05-14 2011-11-09 Arbor Vita Corporation Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
WO2011138778A2 (en) 2010-05-04 2011-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
WO2011138776A2 (en) 2010-05-06 2011-11-10 Hervana Ltd. Biologic female contraceptives
WO2011140234A1 (en) 2010-05-07 2011-11-10 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2011141914A1 (en) 2010-05-13 2011-11-17 Tel Hashomer Medical Research Infrastructure And Services Ltd. Isolated populations of adult renal cells and methods of isolating and using same
WO2011146479A1 (en) 2010-05-18 2011-11-24 The Texas A&M University System Method and composition for the diagnosis and monitoring of inflammatory diseases
EP2390312A1 (en) 2005-11-29 2011-11-30 Gamida Cell Ltd. Methods of improving stem cell homing and engraftment
WO2011151833A1 (en) 2010-06-03 2011-12-08 Ramot At Tel-Aviv University Ltd. Methods of treating diabetes and compositions capable of same
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
EP2395012A2 (en) 2005-11-02 2011-12-14 Protiva Biotherapeutics Inc. Modified siRNA molecules and uses thereof
WO2011154940A1 (en) 2010-06-07 2011-12-15 Osnat Ashur-Fabian Methods and kits for diagnosing conditions related to hypoxia
US8080417B2 (en) 2004-09-16 2011-12-20 Gamida-Cell Ltd. Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
WO2011158242A2 (en) 2010-06-16 2011-12-22 Futuragene Israel Ltd. Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A2 (en) 2010-06-16 2011-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
EP2400030A1 (en) 2004-05-18 2011-12-28 The Board Of Trustees Of The University Of the Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
US8088160B2 (en) 2000-07-20 2012-01-03 Multi-Gene Vascular Systems Ltd. (“MGVS”) Drug-eluting intravascular prostheses and methods of use
EP2402752A2 (en) 2006-10-27 2012-01-04 Janssen Pharmaceutica, N.V. A method for pharmacologically profiling compounds
WO2012006056A2 (en) 2010-06-29 2012-01-12 Oregon Health & Science University Ccr6 as a biomarker of alzheimer's disease
WO2012004759A2 (en) 2010-07-08 2012-01-12 Danisco A/S Method
EP2407242A1 (en) 2010-07-13 2012-01-18 Dublin City University Direct clone analysis and selection technology
WO2012009627A2 (en) 2010-07-16 2012-01-19 Vanderbilt University Low resource processor using surface tension valves for extracting, concentrating and detecting molecular species
WO2012007950A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007919A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
USRE43135E1 (en) 2001-05-18 2012-01-24 Danisco A/S Method of improving dough and bread quality
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
WO2012014205A1 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2 (en) 2010-07-27 2012-02-02 Yeda Research And Development Co. Ltd. Methods and systems for assessing clonality of cell cultures
WO2012018476A1 (en) 2010-07-26 2012-02-09 Abbott Laboratories Antibodies relating to pivka-ii and uses thereof
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
US8114619B2 (en) 2006-03-21 2012-02-14 The Johns Hopkins University Methods for diagnosis and optimizing treatment of multiple sclerosis
EP2423333A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2012025914A1 (en) 2010-08-22 2012-03-01 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
EP2426145A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
EP2425850A2 (en) 2005-06-15 2012-03-07 The Regents of The University of California Bispecific single chain FV antibody molecules and methods of use thereof
EP2426199A2 (en) 2006-10-20 2012-03-07 Danisco US Inc. Polyol oxidases
EP2425841A1 (en) 2000-11-24 2012-03-07 Vascular Biogenics Ltd. Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP2426144A1 (en) 2007-02-23 2012-03-07 Schering Corporation Engineered anti-IL-23p19 antibodies
WO2012032525A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A2 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
WO2012032520A1 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A2 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Ltd. Novel methods and culture media for culturing pluripotent stem cells
WO2012035539A1 (en) 2010-09-15 2012-03-22 Ramot At Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
US8143045B2 (en) 2004-10-04 2012-03-27 Danisco A/S Mutant Citrobacter freundii phytase polypeptide
WO2012038956A1 (en) 2010-09-20 2012-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
WO2012040168A2 (en) 2010-09-20 2012-03-29 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012047724A1 (en) 2010-09-29 2012-04-12 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP2441520A1 (en) 2010-10-12 2012-04-18 Eppendorf AG Real-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2441840A1 (en) 2005-07-18 2012-04-18 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
EP2444099A1 (en) 2005-03-31 2012-04-25 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012052872A2 (en) 2010-10-17 2012-04-26 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012054795A1 (en) 2010-10-21 2012-04-26 Advanced Cell Diagnostics, Inc. An ultra sensitive method for in situ detection of nucleic acids
WO2012056455A1 (en) 2010-10-28 2012-05-03 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
WO2012056452A2 (en) 2010-10-27 2012-05-03 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
EP2450456A2 (en) 2006-11-02 2012-05-09 Yale University Assessment of oocyte competence
WO2012059922A2 (en) 2010-11-03 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012066495A2 (en) 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
EP2457999A2 (en) 2002-12-16 2012-05-30 Technion Research & Development Foundation Ltd. Culture medium for pluropotent stem cells
EP2463382A1 (en) 2010-12-07 2012-06-13 Enterologics, Inc. Method for identifying E. Coli M-17
WO2012081029A1 (en) 2010-12-15 2012-06-21 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
WO2012090205A2 (en) 2010-12-28 2012-07-05 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
WO2012098537A1 (en) 2011-01-20 2012-07-26 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012099896A2 (en) 2011-01-17 2012-07-26 Life Technologies Corporation Workflow for detection of ligands using nucleic acids
WO2012103414A2 (en) 2011-01-28 2012-08-02 Advanced Cell Diagnostics, Inc. Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
US8236493B2 (en) 1994-10-21 2012-08-07 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
WO2012104851A1 (en) 2011-01-31 2012-08-09 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
EP2487182A2 (en) 2005-07-07 2012-08-15 FULCRUM SP Ltd. SP1 polypeptides, modified SP1 polypeptides and uses thereof
WO2012109133A1 (en) 2011-02-07 2012-08-16 Research Development Foundation Engineered immunoglobulin fc polypeptides
US8252588B2 (en) 2003-04-08 2012-08-28 Yeda Research And Development Co. Ltd. Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
WO2012114339A1 (en) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A1 (en) 2011-03-03 2012-09-07 Ramot At Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
WO2012117406A2 (en) 2011-03-02 2012-09-07 Futuragene Israel Ltd. Bacterial resistant transgenic plants
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012120377A2 (en) 2011-03-08 2012-09-13 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
EP2500428A2 (en) 2007-07-11 2012-09-19 Yeda Research and Development Co. Ltd. Nucleic acid construct systems capable of diagnosing or treating a cell state
WO2012123938A1 (en) 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2012123949A1 (en) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012125582A1 (en) 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
WO2012129378A1 (en) 2011-03-22 2012-09-27 Keutgen Xavier M Distinguishing benign and malignant indeterminate thyroid lesions
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012135360A1 (en) 2011-04-01 2012-10-04 Ludwig Institute For Cancer Research Ltd. Binding proteins specific for egfr expressed on tumor and uses thereof
WO2012131594A1 (en) 2011-03-28 2012-10-04 Novartis Ag Markers associated with cyclin-dependent kinase inhibitors
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012137207A1 (en) 2011-04-06 2012-10-11 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012137147A1 (en) 2011-04-08 2012-10-11 Danisco Us, Inc. Compositions
EP2511708A1 (en) 2007-10-05 2012-10-17 Affymetrix, Inc. Highly multiplexed particle-based assays
WO2012140519A2 (en) 2011-04-15 2012-10-18 Pluristem Ltd. Methods and systems for harvesting cells
EP2514763A1 (en) 2004-02-20 2012-10-24 The Ludwig Institute for Cancer Research Egf receptor epitope peptides and uses thereof
EP2520669A2 (en) 2005-02-07 2012-11-07 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
WO2012150600A2 (en) 2011-05-04 2012-11-08 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012150959A1 (en) 2011-05-04 2012-11-08 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
EP2527441A2 (en) 2007-07-15 2012-11-28 Technion Research & Development Foundation Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2526968A2 (en) 2006-01-27 2012-11-28 Biogen Idec MA Inc. Nogo receptor antagonists
EP2526952A1 (en) 2003-07-15 2012-11-28 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
US8323636B2 (en) 2006-02-03 2012-12-04 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2529754A1 (en) 2007-05-03 2012-12-05 Agency For Science, Technology And Research (A*star) Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
WO2012164380A2 (en) 2011-05-31 2012-12-06 Hutchison Biofilm Medical Solutions Limited Dispersion and detachment of cell aggregates
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
EP2532746A2 (en) 2007-03-30 2012-12-12 EnGeneIC Molecular Delivery Pty Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
WO2012172555A1 (en) 2011-06-14 2012-12-20 Yeda Research And Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A1 (en) 2011-06-23 2012-12-27 Kaiima Bio Agritech Ltd. Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
EP2546359A1 (en) 2005-12-08 2013-01-16 Novartis AG Effects of inhibitors of FGFR3 on gene transcription
WO2013010170A1 (en) 2011-07-14 2013-01-17 Lovell Mark A Process for detection of alzheimer's disease from a serum sample
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013011507A1 (en) 2011-07-20 2013-01-24 Kaiima Bio Agritech Ltd. Maize plants having a partially or fully multiplied genome and uses thereof
EP2550982A1 (en) 2011-07-27 2013-01-30 Technion Research & Development Foundation Ltd. Devices for surgical applications
WO2013018060A2 (en) 2011-08-04 2013-02-07 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US8375327B2 (en) 2005-01-16 2013-02-12 Zlango Ltd. Iconic communication
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013022599A1 (en) 2011-08-05 2013-02-14 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013024481A1 (en) 2011-08-14 2013-02-21 Kaiima Bio Agritech Ltd. Durum wheat plants having a partially or fully multiplied genome and uses thereof
EP2561889A2 (en) 2002-08-01 2013-02-27 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US8388954B2 (en) 2003-04-09 2013-03-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013035071A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Novel risk biomarkers for lung cancer
US8415318B2 (en) 2001-10-19 2013-04-09 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2013052643A1 (en) 2011-10-05 2013-04-11 The Rockefeller University Dimeric bacteriophage lysins
EP2581445A1 (en) 2007-08-15 2013-04-17 Yeda Research And Development Co. Ltd. Regulators of MMP-9 and uses thereof
WO2013054331A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US8426166B2 (en) 2006-02-03 2013-04-23 Prolor Biotech Inc. Long-acting polypeptides and methods of producing same
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
WO2013064163A1 (en) 2011-11-01 2013-05-10 Academisch Medisch Centrum Methylation markers for colorectal cancer
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
EP2591789A2 (en) 2007-09-19 2013-05-15 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US8445637B2 (en) 2008-12-05 2013-05-21 Abraxis Bioscience, Llc SPARC binding peptides and uses thereof
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2013076729A1 (en) 2011-11-23 2013-05-30 Danziger Dan Flower Farm Otomeria plants
WO2013076730A1 (en) 2011-11-27 2013-05-30 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis and compositions capable of same
EP2599790A1 (en) 2007-11-26 2013-06-05 Yissum Research Development Company of The Hebrew University of Jerusalem Compositions comprising fibrous polypeptides and polysachharides
WO2013084190A1 (en) 2011-12-08 2013-06-13 Yeda Research And Development Co. Ltd. Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
WO2013098820A1 (en) 2011-12-28 2013-07-04 Kaiima Bio Agritech Ltd. Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013101758A1 (en) 2011-12-29 2013-07-04 Baylor Research Institute Biomarkers for kawasaki disease
WO2013098813A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US8486693B2 (en) 2006-05-23 2013-07-16 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2620493A1 (en) 2008-05-28 2013-07-31 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
US8513488B2 (en) 2007-04-09 2013-08-20 Evogene Ltd. Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US8512990B2 (en) 2009-08-21 2013-08-20 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2013121416A1 (en) 2012-02-14 2013-08-22 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
WO2013121405A1 (en) 2012-02-19 2013-08-22 Protalix Ltd. Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013124816A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
WO2013124817A2 (en) 2012-02-22 2013-08-29 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013126803A1 (en) 2012-02-24 2013-08-29 Protiva Biotherapeutics Inc. Trialkyl cationic lipids and methods of use thereof
EP2633854A1 (en) 2008-12-05 2013-09-04 Yeda Research And Development Co. Ltd. miRNA-9 or miRNA-9* for use in treating MND
WO2013130811A1 (en) 2012-02-29 2013-09-06 Chemocentryx, Inc. Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
WO2013128454A1 (en) 2012-03-01 2013-09-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
EP2636743A1 (en) 2006-04-21 2013-09-11 Intervet International B.V. Pestivirus species
WO2013132495A1 (en) 2012-03-07 2013-09-12 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A1 (en) 2012-03-15 2013-09-19 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2013140389A1 (en) 2012-03-22 2013-09-26 Ramot At Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
WO2013149219A2 (en) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
WO2013152295A1 (en) 2012-04-05 2013-10-10 Advanced Cell Diagnostics, Inc. Detection of immunoglobulin light chain restrication by rna in situ hybridization
WO2013153553A2 (en) 2012-04-13 2013-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for controlling varroa mites in bees
US8569025B2 (en) 2009-06-29 2013-10-29 The University Of British Columbia Terpene synthases from santalum
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2013163035A1 (en) 2012-04-23 2013-10-31 Uhl Ii, Llc Devices and methods for detecting analyte in bodily fluid
WO2013170168A1 (en) 2012-05-10 2013-11-14 Bioatla Llc Multi-specific monoclonal antibodies
WO2013168164A1 (en) 2012-05-09 2013-11-14 Yeda Research And Development Co. Ltd. Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013183052A1 (en) 2012-06-04 2013-12-12 Prolor Biotech Inc. Pegylated oxm variants
WO2013183048A1 (en) 2012-06-03 2013-12-12 Ben-Gurion University Of The Negev Research And Development Authority Functionalized titanium binding peptides and implants coated with same
EP2674440A2 (en) 2005-12-16 2013-12-18 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US8613926B2 (en) 2011-06-06 2013-12-24 Novo Nordisk A/S Anti-C5a receptor antibodies
WO2013192616A1 (en) 2012-06-22 2013-12-27 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
US8617551B2 (en) 1995-02-17 2013-12-31 Incyte Corporation Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
EP2679599A1 (en) 2008-02-20 2014-01-01 Amgen Inc. Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
WO2014006621A1 (en) 2012-07-03 2014-01-09 Nanospun Technologies Ltd. Methods and devices for adsorption and biodegradation of petroleum
US8629250B2 (en) 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
WO2014011398A1 (en) 2012-07-09 2014-01-16 Novartis Ag Biomarkers associated with cdk inhibitors
WO2014011881A2 (en) 2012-07-11 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014014788A2 (en) 2012-07-18 2014-01-23 President And Fellows Of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
WO2014020599A1 (en) 2012-07-29 2014-02-06 Yeda Research And Development Co. Ltd. Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A1 (en) 2012-07-31 2014-02-06 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
WO2014020502A2 (en) 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
WO2014024183A1 (en) 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2014033723A1 (en) 2012-09-03 2014-03-06 A.B. Seeds Ltd. Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A1 (en) 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US8686227B2 (en) 2007-07-24 2014-04-01 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2712620A1 (en) 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP2716654A1 (en) 2005-10-24 2014-04-09 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
WO2014057490A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014062635A1 (en) 2012-10-19 2014-04-24 Novartis Ag Markers for acute lymphoblastic leukemia
WO2014063097A1 (en) 2012-10-19 2014-04-24 Danisco Us Inc. Stabilization of biomimetic membranes
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
WO2014064682A1 (en) 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
WO2014068553A1 (en) 2012-10-29 2014-05-08 Yeda Research And Development Co. Ltd. Aptamers, multimeric aptamers and uses thereof
WO2014083567A2 (en) 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8775526B2 (en) 2006-01-16 2014-07-08 Zlango Ltd. Iconic communication
WO2014106838A2 (en) 2013-01-01 2014-07-10 A.B. Seeds Ltd. Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en) 2013-01-09 2014-07-17 Yeda Research And Development Co. Ltd. High throughput transcriptome analysis
WO2014111936A1 (en) 2013-01-17 2014-07-24 Novellusdx Ltd. Methods and systems for identifying patient specific driver mutations
US8791232B2 (en) 2008-04-30 2014-07-29 Dupont Nutrition Biosciences Aps Proteins
WO2014121077A2 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US8828386B2 (en) 2002-07-25 2014-09-09 Glenveigh Pharmaceuticals, Llc Method for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia
EP2774987A1 (en) 2006-08-17 2014-09-10 Affymetrix, Inc. Nucleic acid quantitation from tissue slides
WO2014136113A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136117A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014141038A2 (en) 2013-03-11 2014-09-18 Irm Llc Markers associated with wnt inhibitors
WO2014144170A1 (en) 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production using non-human act1 -deficient mice
EP2781223A1 (en) 2007-10-19 2014-09-24 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014147622A1 (en) 2013-03-21 2014-09-25 Collplant Ltd. Compositions comprising collagen and prp for tissue regeneration
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8847008B2 (en) 2008-05-22 2014-09-30 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
WO2014155376A1 (en) 2013-03-24 2014-10-02 Biokine Therapeutics Ltd. Methods of treating myeloid leukemia
US8859467B2 (en) 2009-07-17 2014-10-14 Bioatla, Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
EP2789626A2 (en) 2008-09-24 2014-10-15 Tel Hashomer Medical Research Infrastructure and Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
WO2014176047A1 (en) 2013-04-25 2014-10-30 Novartis Ag Markers for ezh2 inhibitors
WO2014174470A1 (en) 2013-04-23 2014-10-30 Yeda Research And Development Co. Ltd. Isolated naive pluripotent stem cells and methods of generating same
WO2014174520A1 (en) 2013-04-25 2014-10-30 Yeda Research And Development Co. Ltd. Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014174511A1 (en) 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
EP2808344A1 (en) 2010-06-01 2014-12-03 Monash University Antibodies directed to the receptor tyrosine kinase c-Met
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
EP2816117A2 (en) 2004-09-29 2014-12-24 Collplant Ltd. Collagen producing plants and methods of generating and using same
WO2014204814A1 (en) 2013-06-18 2014-12-24 Dnatrix, Inc. Treatment of brain cancer with oncolytic adenovirus
WO2014207744A1 (en) 2013-06-24 2014-12-31 Ramot At Tel-Aviv University Ltd. Omentum based scaffold and delivery system
US8940519B2 (en) 2009-04-24 2015-01-27 Dupont Nutrition Biosciences Aps Method of producing a lipolytic enzyme
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
WO2015017552A1 (en) 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
EP2839839A1 (en) 2007-02-28 2015-02-25 Yeda Research And Development Company Limited Nuclear targeting sequences
US8975016B2 (en) 2009-04-16 2015-03-10 Diagnostic Hybrids, Inc. Methods for direct fluorescent antibody virus detection in liquids
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015033337A1 (en) 2013-09-03 2015-03-12 Technion Research & Development Foundation Limited. A flap for de-novo tissue regeneration
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
US9018445B2 (en) 2008-08-18 2015-04-28 Evogene Ltd. Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A1 (en) 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9040667B2 (en) 2009-05-01 2015-05-26 Dako Denmark A/S Antibody cocktail
WO2015079413A2 (en) 2013-11-28 2015-06-04 Yeda Research And Development Co. Ltd. Synaptojanin-2 inhibitors and uses thereof
US9057092B2 (en) 2006-03-06 2015-06-16 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2015094527A1 (en) 2013-12-19 2015-06-25 Danisco Us Inc. Use of hydrophobins to increase gas transferin aerobic fermentation processes
EP2889041A1 (en) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit of reagents for tuberculosis assay
US9096865B2 (en) 2009-06-10 2015-08-04 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
US9096645B2 (en) 2010-11-15 2015-08-04 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2015116753A1 (en) 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A1 (en) 2014-02-06 2015-08-13 Yeda Research And Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015120273A1 (en) 2014-02-07 2015-08-13 The General Hospital Corporation Differential diagnosis of hepatic neoplasms
WO2015118547A1 (en) 2014-02-10 2015-08-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2015123565A1 (en) 2014-02-14 2015-08-20 The General Hospital Corporation Methods for diagnosing igg4-related disease
WO2015121859A1 (en) 2014-02-11 2015-08-20 Brainstorm Cell Therapeutics Ltd. Method of qualifying cells
US9121022B2 (en) 2010-03-08 2015-09-01 Monsanto Technology Llc Method for controlling herbicide-resistant plants
WO2015131099A1 (en) 2014-02-28 2015-09-03 The General Hospital Corporation Diagnosis of multiple myeloma and lymphoma
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
WO2015132784A1 (en) 2014-03-03 2015-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en) 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
EP2933265A2 (en) 2005-06-03 2015-10-21 Amicus Therapeutics, Inc. Pharmacological chaperones for treating obesity
WO2015159295A1 (en) 2014-04-17 2015-10-22 Yeda Research And Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
WO2015159293A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
EP2936976A1 (en) 2008-04-21 2015-10-28 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2015166492A2 (en) 2014-04-28 2015-11-05 Yeda Research And Development Co. Ltd. Microbiome response to agents
US9182403B2 (en) 2009-05-19 2015-11-10 Zetiq Technologies Ltd. Kits for and methods of differential staining of cervical cancer cells and/or tissues
EP2942627A1 (en) 2014-05-05 2015-11-11 MicroBPlex, Inc. Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
WO2015170320A2 (en) 2014-05-04 2015-11-12 Forrest Innovations Ltd. Compositions and methods of using same for controlling pathogenically infected mosquitoes
EP2944649A1 (en) 2008-01-10 2015-11-18 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2015177800A2 (en) 2014-05-22 2015-11-26 Yeda Research And Development Co. Ltd. Recombinant microorganisms capable of carbon fixation
WO2015186129A1 (en) 2014-06-02 2015-12-10 Technion Research & Development Foundation Limited. Compositions and methods of selectively inhibiting irp1 and treating inflammation
US9212258B2 (en) 2011-02-23 2015-12-15 The Board Of Trustees Of The University Of Illinois Amphiphilic dendron-coils, micelles thereof and uses
WO2015198334A2 (en) 2014-06-25 2015-12-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells and use of same for diagnosis and treatment
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
US9238843B2 (en) 2010-12-27 2016-01-19 Eli Lilly And Company Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines
WO2016009436A1 (en) 2014-07-15 2016-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
US9261462B2 (en) 2011-12-12 2016-02-16 Step Ahead Innovations, Inc. Monitoring of photo-aging of light-based chemical indicators using illumination-brightness differential scheme
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
EP2990421A1 (en) 2009-04-30 2016-03-02 Tel HaShomer Medical Research Infrastructure and Services Ltd. Anti ceacam1 antibodies and methods of using same
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
WO2016038609A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
WO2016042561A2 (en) 2014-09-21 2016-03-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Downregulating mir-132 for the treatment of lipid related disorders
EP3006039A1 (en) 2004-03-02 2016-04-13 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US9316641B2 (en) 2010-01-11 2016-04-19 Biogen Ma Inc. Assay for JC virus antibodies
WO2016061111A1 (en) 2014-10-13 2016-04-21 Life Technologies Corporation Methods, kits & compositions for determining gene copy numbers
WO2016062855A1 (en) 2014-10-24 2016-04-28 Dupont Nutrition Biosciences Aps Proline tolerant tripeptidyl peptidases and uses thereof
WO2016065238A1 (en) 2014-10-24 2016-04-28 Danisco Us Inc. Method for producing alcohol by use of a tripeptidyl peptidase
EP3018139A2 (en) 2007-08-03 2016-05-11 Boehringer Ingelheim Vetmedica GmbH Genes and proteins of brachyspira hyodysenteriae and uses thereof
EP3020410A1 (en) 2008-04-18 2016-05-18 Collplant Ltd. Methods of generating and using procollagen
DE102015220401A1 (en) 2014-10-20 2016-05-19 Gen-Probe Incorporated Erythrocyte lysis solution
EP3023438A1 (en) 2009-09-03 2016-05-25 Merck Sharp & Dohme Corp. Anti-gitr antibodies
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
WO2016079731A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Method of analyzing microbiome
WO2016079739A2 (en) 2014-11-20 2016-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
EP3026057A2 (en) 2009-03-09 2016-06-01 Ramot at Tel Aviv University Ltd. Compositions for prevention and treatment of neurodegenerative diseases
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
WO2016092555A2 (en) 2014-12-11 2016-06-16 Yeda Research And Development Co. Ltd. Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
WO2016108239A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
WO2016108244A1 (en) 2015-01-04 2016-07-07 Protalix Ltd. Modified dnase and uses thereof
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
US9411930B2 (en) 2013-02-01 2016-08-09 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US9422558B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
US9422557B2 (en) 2011-09-13 2016-08-23 Monsanto Technology Llc Methods and compositions for weed control
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
US9434985B2 (en) 2008-09-25 2016-09-06 University Of Massachusetts Methods of identifying interactions between genomic loci
WO2016142948A1 (en) 2015-03-11 2016-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
US9447454B2 (en) 2003-10-23 2016-09-20 The Rockefeller University Method of purifying RNA binding protein-RNA complexes
WO2016147194A1 (en) 2015-03-19 2016-09-22 Yeda Research And Development Co. Ltd. Anti amphiregulin antibodies, compositions comprising same and uses thereof
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458438B2 (en) 2010-04-12 2016-10-04 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
WO2016157190A1 (en) 2015-03-31 2016-10-06 Yeda Research And Development Co. Ltd. Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016162870A1 (en) 2015-04-07 2016-10-13 Ilana Nathan Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US9476884B2 (en) 2013-10-04 2016-10-25 University Of Massachusetts Hybridization- independent labeling of repetitive DNA sequence in human chromosomes
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
WO2016174674A1 (en) 2015-04-27 2016-11-03 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
US9487559B2 (en) 2010-10-04 2016-11-08 Elro Pharma Sarl Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
EP3091026A1 (en) 2015-05-08 2016-11-09 Centrillion Technology Holdings Corporation Disulfide-linked reversible terminators
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
WO2016185469A1 (en) 2015-05-21 2016-11-24 Yeda Research And Development Co. Ltd. Bacterial populations for promoting health
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
WO2016199140A1 (en) 2015-06-08 2016-12-15 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
WO2016203476A1 (en) 2015-06-18 2016-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A1 (en) 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
US9528998B2 (en) 2010-04-16 2016-12-27 Abbott Laboratories Methods and reagents for diagnosing rheumatoid arthrtis
WO2016210395A1 (en) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases for protein hydrlyzates
US9540642B2 (en) 2013-11-04 2017-01-10 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods for controlling arthropod parasite and pest infestations
EP3115451A1 (en) 2008-09-02 2017-01-11 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
WO2017009853A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US9551006B2 (en) 2010-12-22 2017-01-24 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
WO2017013661A1 (en) 2015-07-22 2017-01-26 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2017017686A1 (en) 2015-07-29 2017-02-02 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
WO2017021961A1 (en) 2015-08-04 2017-02-09 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
WO2017021972A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2017025967A1 (en) 2015-08-13 2017-02-16 Forrest Innovations Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2017033188A1 (en) 2015-08-24 2017-03-02 Yeda Research And Development Co. Ltd. Algal oil and biofuel and methods of producing same
WO2017033152A1 (en) 2015-08-25 2017-03-02 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
US9611315B2 (en) 2003-12-23 2017-04-04 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
WO2017059108A1 (en) 2015-09-29 2017-04-06 Htg Molecular Diagnostics, Inc. Methods for subtyping diffuse b-cell lymphoma (dlbcl)
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP3159405A1 (en) 2010-01-05 2017-04-26 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2017072757A1 (en) 2015-10-25 2017-05-04 Yeda Research And Development Co. Ltd. Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072772A1 (en) 2015-10-29 2017-05-04 Yeda Research And Development Co. Ltd. A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072763A1 (en) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
WO2017072773A1 (en) 2015-10-27 2017-05-04 Ilana Nathan Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017077539A1 (en) 2015-11-03 2017-05-11 Ariel-University Research And Development Company Ltd. Compositions for regeneration and repair of neural tissue
US9650436B2 (en) 2012-10-12 2017-05-16 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
WO2017109679A1 (en) 2015-12-21 2017-06-29 Novartis Ag Compositions and methods for decreasing tau expression
WO2017118985A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US9715573B2 (en) 2015-02-17 2017-07-25 Dovetail Genomics, Llc Nucleic acid sequence assembly
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US9726581B2 (en) 2011-12-22 2017-08-08 Realbio Technologies Ltd. Sequential lateral flow capillary device for analyte determination
WO2017134671A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
WO2017138008A2 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2017138007A1 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Microbiome-based diagnosis, prediction and treatment of relapsing obesity
US9739773B1 (en) 2010-08-13 2017-08-22 David Gordon Bermudes Compositions and methods for determining successful immunization by one or more vaccines
WO2017141253A1 (en) 2016-02-16 2017-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017147060A1 (en) 2016-02-25 2017-08-31 Dupont Nutrition Biosciences Aps Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
WO2017147186A1 (en) 2016-02-22 2017-08-31 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
WO2017158610A1 (en) 2016-03-17 2017-09-21 Yeda Research And Development Co. Ltd. Methods of isolating barrel-like proteases and identifying peptides processed thereby
US9777288B2 (en) 2013-07-19 2017-10-03 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
WO2017172518A1 (en) 2016-03-29 2017-10-05 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
US9784686B2 (en) 2013-06-19 2017-10-10 Step Ahead Innovations, Inc. Aquatic environment water parameter testing systems and methods
US9796762B2 (en) 2013-04-10 2017-10-24 4D Pharma Research Limited Polypeptide and immune modulation
WO2017189746A1 (en) 2016-04-27 2017-11-02 Gen-Probe Incorporated Blood cell lysis reagent
US9808534B2 (en) 2012-11-20 2017-11-07 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US9822134B2 (en) 2012-10-22 2017-11-21 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US9828417B2 (en) 2006-02-03 2017-11-28 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171930C (en) * 1972-05-11 1983-06-01 Akzo Nv Method for the detection and determination of haptens, as well as test packs.
US3790447A (en) * 1972-07-05 1974-02-05 Abbott Lab Streptococci diagnostic method
JPS5734904B2 (en) * 1976-09-29 1982-07-26
GB1589208A (en) * 1977-03-16 1981-05-07 Miles Yeda Ltd Immunoassay
ES8602088A1 (en) * 1983-07-25 1985-11-01 Becton Dickinson Co Tracer for use in assay
DE3433652A1 (en) * 1984-09-13 1986-03-20 Boehringer Mannheim Gmbh Immunochemical measurement method for haptenic and proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615222A (en) * 1968-09-04 1971-10-26 New England Nuclear Corp Method and apparatus for measuring the amount of a component in a biological fluid
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615222A (en) * 1968-09-04 1971-10-26 New England Nuclear Corp Method and apparatus for measuring the amount of a component in a biological fluid
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3654090B1 (en) * 1968-09-24 1982-07-20

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 65: 11124b, (1966). *
Spector et al., 168: 1348, 8, Science, (June 12, 1970). *

Cited By (1729)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630328B2 (en) 1909-07-15 2003-10-07 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4191613A (en) * 1971-05-14 1980-03-04 Syva Company Malate dehydrogenase conjugates for enzyme immunoassays
US4282325A (en) * 1971-05-14 1981-08-04 Syva Company Enzyme bound corticosteroids
US4203802A (en) * 1971-05-14 1980-05-20 Syva Company Inhibitable enzyme amplification assay
US3905871A (en) * 1971-05-14 1975-09-16 Syva Co Lactam conjugates to enzymes
US4039385A (en) * 1972-05-08 1977-08-02 Syva Company Cardiac glycoside enzyme conjugates
US3966556A (en) * 1972-11-06 1976-06-29 Syva Company Compounds for enzyme amplification assay methadone analogs
US3975237A (en) * 1972-11-06 1976-08-17 Syva Company Compounds for enzyme amplification assay - - ecgonine analogs
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4046636A (en) * 1974-06-20 1977-09-06 Syva Company Diazepam enzyme conjugates
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
US4343896A (en) * 1975-02-01 1982-08-10 Akzona Incorporated Method and test pack for the demonstration and determination of an antigen or antibody
US4043872A (en) * 1975-02-20 1977-08-23 Syva Company Polyiodothyronine immunoassay
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4096138A (en) * 1975-12-08 1978-06-20 Scherr George H Immunological test procedure
US4166767A (en) * 1976-03-25 1979-09-04 Dainippon Pharmaceutical Co., Ltd. Insolubilized antibody
US4248965A (en) * 1976-10-07 1981-02-03 Mochida Seiyaku Kabushiki Kaisha Immunochemical process of measuring physiologically active substances
FR2367286A1 (en) * 1976-10-07 1978-05-05 Mochida Pharm Co Ltd New process and immunochemical assay reagents physiologically active substances
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
US4250253A (en) * 1977-03-15 1981-02-10 Snamprogetti S.P.A. Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same
DE2805961A1 (en) * 1977-04-15 1978-10-19 Syva Co Theophylline antigens and antibodies and their use for determination of theophylline
FR2390732A1 (en) * 1977-05-12 1978-12-08 Sclavo Inst Sieroterapeut A method for determining the levels of certain components of biological fluids and means implemented
US5955262A (en) * 1978-04-13 1999-09-21 Institut Pasteur Method of detecting and characterizing a nucleic acid or reactant for the application of this method
US5876928A (en) * 1978-04-13 1999-03-02 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US4467030A (en) * 1978-06-12 1984-08-21 Boehringer Mannheim Gmbh Determination of the thyroxine-binding index in serum
US4269938A (en) * 1979-03-08 1981-05-26 Eastman Kodak Company Assay of peroxidatively active materials
US4376825A (en) * 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4350761A (en) * 1979-05-18 1982-09-21 Yamasu Shoyu Kabushiki Kaisha Method of and reagents for quantitative analysis of cyclic nucleotides
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
WO1980002747A1 (en) * 1979-05-31 1980-12-11 Rapidex Ltd Ultrasensitive enzymatic radioimmunoassay method
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4347312A (en) * 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
US4443365A (en) * 1980-07-01 1984-04-17 Dainippon Pharmaceutical Company Limited Method for determination of the valproic acid and reagents therein
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
WO1982004323A1 (en) * 1981-06-02 1982-12-09 O Neill Sean Immunoprecipitation assay
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
US4419453A (en) * 1981-09-28 1983-12-06 The Dow Chemical Company Immunological agglutination assays with dyed or colored latex and kits
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4535057A (en) * 1982-07-26 1985-08-13 Amf Incorporated Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
WO1985000605A1 (en) * 1983-07-27 1985-02-14 American Hospital Supply Corporation Process for selective nitrile reduction
US5047330A (en) * 1983-08-17 1991-09-10 Commissariat A L'energie Atomique Compound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US4713347A (en) * 1985-01-14 1987-12-15 Sensor Diagnostics, Inc. Measurement of ligand/anti-ligand interactions using bulk conductance
US4786594A (en) * 1986-05-14 1988-11-22 Syntex (U.S.A.) Inc. Enzyme immunoassay
US6103234A (en) * 1988-09-02 2000-08-15 The Rockefeller University Composition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)
US5717074A (en) * 1988-09-02 1998-02-10 The Rockefeller University Macrophage-derived inflammatory mediator (MIP-2)
EP0703296A1 (en) 1988-09-29 1996-03-27 Chiron Corporation Polynucleotide determination by strand replacement of a capture probe
US5652346A (en) * 1990-07-27 1997-07-29 Johnson & Johnson Clinical Diagnostics, Inc. Dicarboxylic acid oxidation products
US5391483A (en) * 1990-07-27 1995-02-21 Eastman Kodak Company Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5268298A (en) * 1991-04-26 1993-12-07 Life Technologies, Inc. System for delivering oxygen to a cell culture medium
US5587294A (en) * 1991-07-19 1996-12-24 Assay Research, Inc. Method and kit for measuring endogenous cytokines
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
EP0524502A2 (en) 1991-07-22 1993-01-27 Bayer Corporation Immunoassay for free analyte
US5939524A (en) * 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5733546A (en) * 1991-12-20 1998-03-31 The Rockefeller University Immunochemical detection of in vivo advanced glycosylation endproducts
US5629408A (en) * 1991-12-20 1997-05-13 The Rockefeller University Immunochemical isolation of in vivo advanced glycosylation endproducts
US5702704A (en) * 1991-12-20 1997-12-30 The Rockefeller University Antibodies to in vivo advanced glycosylation endproducts
US5712101A (en) * 1991-12-20 1998-01-27 The Rockefeller University Immunochemical detection of in vivo advanced glycosylation endproducts
US5683887A (en) * 1991-12-20 1997-11-04 The Rockefeller University Immunochemical detection of in vivo advanced glycosylation endproducts
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US7988972B2 (en) 1992-09-15 2011-08-02 Ortho-Clinical Diagnostics, Inc. Immunoreactive peptides from Epstein-Barr virus
US7060283B1 (en) 1992-09-15 2006-06-13 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US5637467A (en) * 1992-10-13 1997-06-10 Behringwerke Ag Heterogeneous assay using a pendulous drop
US5846538A (en) * 1993-03-17 1998-12-08 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US7601697B2 (en) 1993-03-17 2009-10-13 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US8524491B2 (en) 1993-03-17 2013-09-03 University Of Washington Through Its Center For Commercialization Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20080076904A1 (en) * 1993-03-17 2008-03-27 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7247703B2 (en) 1993-03-17 2007-07-24 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6075122A (en) * 1993-03-17 2000-06-13 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5876712A (en) * 1993-03-17 1999-03-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US7655239B2 (en) 1993-03-17 2010-02-02 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20040082758A1 (en) * 1993-03-17 2004-04-29 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US6664370B2 (en) 1993-03-17 2003-12-16 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US20050191285A1 (en) * 1993-03-17 2005-09-01 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US20020055617A1 (en) * 1993-06-18 2002-05-09 Marilyn H. Perrin Cloning and recombinant production of cfr receptor(s)
US6495343B1 (en) 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6482608B1 (en) * 1993-06-18 2002-11-19 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(S)
US7358225B2 (en) 1993-06-18 2008-04-15 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6638905B2 (en) 1993-06-18 2003-10-28 The Salk Institute For Biological Studies Cloning and recombinant production of CFR receptor(s)
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US5684144A (en) * 1993-07-28 1997-11-04 University Of North Texas Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US20040013665A1 (en) * 1993-09-15 2004-01-22 Ortho Diagnostic Systems, Inc. Immunoreactive peptides from Epstein-Barr virus
US7326535B2 (en) 1993-09-15 2008-02-05 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
EP2364994A1 (en) 1994-01-05 2011-09-14 Schering Corporation Purfied primate CTLA-8 antigens and related reagents
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US6008335A (en) * 1994-02-11 1999-12-28 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and Crohn's disease
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6613514B2 (en) 1994-02-17 2003-09-02 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6319713B1 (en) 1994-02-17 2001-11-20 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6355484B1 (en) 1994-02-17 2002-03-12 Maxygen, Inc. Methods and compositions for polypeptides engineering
US6093796A (en) * 1994-05-10 2000-07-25 Mayo Foundation For Medical Education And Research Recombinant hK2 polypeptide
US6013471A (en) * 1994-05-10 2000-01-11 Hybritech Incorporated DNA encoding hK2 variant polypeptides
US5837535A (en) * 1994-06-13 1998-11-17 Henry Ford Health System Neuronal-neonatal gene: neuronatin
US5589344A (en) * 1994-06-15 1996-12-31 Johnson & Johnson Clinical Diagnostics, Inc. Test kit and method for competitive specific binding assay
EP0705902A1 (en) 1994-08-12 1996-04-10 Myriad Genetics, Inc. 17q-Linked breast and ovarian cancer susceptibility gene
EP0705903A1 (en) 1994-08-12 1996-04-10 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
EP0699754A1 (en) 1994-08-12 1996-03-06 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
US8173793B2 (en) 1994-08-17 2012-05-08 The Rockefeller University Nucleic acids encoding modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US7994301B2 (en) 1994-08-17 2011-08-09 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP2402444A1 (en) 1994-08-17 2012-01-04 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20060292579A1 (en) * 1994-10-21 2006-12-28 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface bound double-stranded DNA
US8236493B2 (en) 1994-10-21 2012-08-07 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US7708984B2 (en) 1994-12-07 2010-05-04 Incyte Corporation Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid
US20080138346A1 (en) * 1994-12-07 2008-06-12 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
US8008027B2 (en) 1994-12-07 2011-08-30 Incyte Corporation Methods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US9090687B2 (en) 1995-02-17 2015-07-28 Incyte Corporation Methods of treating pancreatitis
US8617551B2 (en) 1995-02-17 2013-12-31 Incyte Corporation Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
US6506553B1 (en) 1995-03-30 2003-01-14 Ortho Diagnostics Systems, Inc. Method for diagnosis of Epstein-Barr virus associated disease
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US6200749B1 (en) 1995-05-16 2001-03-13 Ramot-University Authority For Applied Research And Industrial Development Ltd. Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US6946296B2 (en) 1995-11-30 2005-09-20 Maxygen, Inc. Methods and compositions for polypeptide engineering
EP0785216A1 (en) 1995-12-18 1997-07-23 Myriad Genetics, Inc. Chomosome 13-linked breast cancer susceptibility gene BRCA2
EP2338913A1 (en) 1995-12-18 2011-06-29 The University of Utah Research Foundation Chromosome 13-linked breast cancer susceptibility gene
US7423143B2 (en) 1996-01-23 2008-09-09 Affymetrix. Inc. Nucleic acid labeling compounds
US6965020B2 (en) 1996-01-23 2005-11-15 Affymetrix, Inc. Nucleic acid labeling compounds
US20030180757A1 (en) * 1996-01-23 2003-09-25 Affymetrix, Inc. Nucleic acid labeling compounds
US6858711B2 (en) 1996-01-23 2005-02-22 Affymetrix, Inc. Labeling reagents
US6864059B2 (en) 1996-01-23 2005-03-08 Affymetrix, Inc. Biotin containing C-glycoside nucleic acid labeling compounds
US7291463B2 (en) 1996-01-23 2007-11-06 Affymetrix, Inc. Nucleic acid labeling compounds
US20030064364A1 (en) * 1996-01-23 2003-04-03 Lockhart David J. Nucleic acid analysis techniques
US20040101892A1 (en) * 1996-01-23 2004-05-27 Affymetrix, Inc. Nucleic acid labeling compounds
US20040210045A1 (en) * 1996-01-23 2004-10-21 Mcgall Glenn Nucleic acid labeling compounds
US20050287563A1 (en) * 1996-01-23 2005-12-29 Affymetrix, Inc. Nucleic acid labeling compounds
US7282327B2 (en) 1996-01-23 2007-10-16 Affymetrix, Inc. Nucleic acid labeling compounds
US6924094B1 (en) 1996-02-08 2005-08-02 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US20060204970A1 (en) * 1996-02-08 2006-09-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
EP1728875A2 (en) 1996-02-08 2006-12-06 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US7252948B2 (en) 1996-02-08 2007-08-07 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US6129917A (en) * 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US20060008479A1 (en) * 1996-04-01 2006-01-12 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6207153B1 (en) 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20040091484A1 (en) * 1996-05-22 2004-05-13 Dan Michael D. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US7166286B2 (en) 1996-05-22 2007-01-23 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US6312901B2 (en) 1996-07-08 2001-11-06 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US20020106661A1 (en) * 1996-07-08 2002-08-08 Burstein Laboratories, Inc. Optical disk-based assay devices and methods
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
EP1947183A1 (en) 1996-08-16 2008-07-23 Schering Corporation Mammalian cell surface antigens; related reagents
US20070082371A1 (en) * 1996-09-24 2007-04-12 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20040039184A1 (en) * 1996-09-24 2004-02-26 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070077574A1 (en) * 1996-09-24 2007-04-05 Tanox, Inc. family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6433155B1 (en) 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7045596B2 (en) 1996-09-24 2006-05-16 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070071751A1 (en) * 1996-09-24 2007-03-29 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7576187B2 (en) 1996-09-24 2009-08-18 Genentech, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7045604B2 (en) 1996-09-24 2006-05-16 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US7005262B2 (en) 1996-10-01 2006-02-28 Geron Corporation Methods for detecting nucleic acids encoding human telomerase reverse transcriptase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7195911B2 (en) 1996-10-01 2007-03-27 Geron Corporation Mammalian cells that have increased proliferative capacity
US20030096344A1 (en) * 1996-10-01 2003-05-22 Cech Thomas R. Human telomerase catalytic subunit: diagnostic and therapeutic methods
EP1783139A2 (en) 1996-10-01 2007-05-09 Geron Corporation Human telomerase catalytic subunit
US20090269739A1 (en) * 1996-10-01 2009-10-29 Geron Corporation Kit for detection of telomerase reverse transcriptase nucleic acids
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US8222392B2 (en) 1996-10-01 2012-07-17 Geron Corporation Kit for detection of telomerase reverse transcriptase nucleic acids
US20070190561A1 (en) * 1996-10-01 2007-08-16 Geron Corporation Segments of the Human Gene for Telomerase Reverse Transcriptase
EP1333094A2 (en) 1996-10-01 2003-08-06 Geron Corporation Human telomerase catalytic subunit
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US7517971B1 (en) 1996-10-01 2009-04-14 Geron Corporation Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6921664B2 (en) 1996-10-01 2005-07-26 Regents Of The University Of Colorado Telomerase
EP2213740A1 (en) 1996-10-01 2010-08-04 The Regents of the University of Colorado Human telomerase catalytic subunit
US7285639B2 (en) 1996-10-01 2007-10-23 Geron Corporation Antibody to telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7560437B2 (en) 1996-10-01 2009-07-14 Geron Corporation Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
US6617110B1 (en) 1996-10-01 2003-09-09 Geron Corporation Cells immortalized with telomerase reverse transcriptase for use in drug screening
US7879609B2 (en) 1996-10-01 2011-02-01 Geron Corporation Regulatory segments of the human gene for telomerase reverse transcriptase
WO1998014593A2 (en) 1996-10-01 1998-04-09 Geron Corporation Human telomerase catalytic subunit
US7056513B2 (en) 1996-10-01 2006-06-06 Geron Corporation Telomerase
US6927285B2 (en) 1996-10-01 2005-08-09 Geron Corporation Genes for human telomerase reverse transcriptase and telomerase variants
US20020187471A1 (en) * 1996-10-01 2002-12-12 Cech Thomas R. Novel telomerase
US20030100093A1 (en) * 1996-10-01 2003-05-29 Cech Thomas R. Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6294334B1 (en) 1996-11-15 2001-09-25 Board Of Regents, The University Of Texas System Genetic test for equine severe combined immunodeficiency disease
EP1995318A1 (en) 1996-12-13 2008-11-26 Schering Corporation Mammalian cell surface antigens; related reagents
EP1995317A1 (en) 1996-12-13 2008-11-26 Schering Corporation Mammalian cell surface antigens; related reagents
EP1803816A2 (en) 1996-12-13 2007-07-04 Schering Corporation Mammalian cell surface antigens; related reagents
US6653072B1 (en) 1996-12-18 2003-11-25 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060166225A1 (en) * 1996-12-18 2006-07-27 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060084091A1 (en) * 1996-12-18 2006-04-20 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6579678B1 (en) 1996-12-18 2003-06-17 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6303344B1 (en) 1996-12-18 2001-10-16 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6455253B1 (en) 1996-12-18 2002-09-24 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
EP2172478A2 (en) 1997-02-07 2010-04-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor III (ADNF III)
US20020193310A1 (en) * 1997-04-01 2002-12-19 Bishwajit Nag Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6127338A (en) * 1997-04-01 2000-10-03 Calyx Therapeutics, Inc. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6391854B1 (en) 1997-04-01 2002-05-21 Calyx Therapeutics, Inc. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US6852695B2 (en) 1997-04-01 2005-02-08 Theracos, Inc. Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
US8236774B2 (en) 1997-04-18 2012-08-07 Geron Corporation Human telomerase catalytic subunit
US20040242529A1 (en) * 1997-04-18 2004-12-02 Geron Corporation Vector encoding inactivated telomerase for treating cancer
US20060040307A1 (en) * 1997-04-18 2006-02-23 Geron Corporation Human telomerase catalytic subunit
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7262288B1 (en) 1997-04-18 2007-08-28 Geron Corporation Nucleic acids encoding human telomerase reverse transcriptase and related homologs
US8709995B2 (en) 1997-04-18 2014-04-29 Geron Corporation Method for eliciting an immune response to human telomerase reverse transcriptase
US20080279871A1 (en) * 1997-04-18 2008-11-13 Geron Corporation Immunogenic composition
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7750121B2 (en) 1997-04-18 2010-07-06 Geron Corporation Antibody to telomerase reverse transcriptive
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20060188944A1 (en) * 1997-06-05 2006-08-24 Barak Lawrence S Methods of assaying receptor activity
US6770449B2 (en) 1997-06-05 2004-08-03 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7138240B2 (en) 1997-06-05 2006-11-21 Duke University Methods of assaying receptor activity
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US20080261256A1 (en) * 1997-06-05 2008-10-23 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7572888B2 (en) 1997-06-05 2009-08-11 Duke University Methods of assaying receptor activity and constructs useful in such methods
US20040209308A1 (en) * 1997-06-05 2004-10-21 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6235486B1 (en) 1997-06-20 2001-05-22 Mayo Foundation For Medical Education & Research Method for detection of breast cancer
US20030118593A1 (en) * 1997-07-08 2003-06-26 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EP1980573A2 (en) 1997-07-09 2008-10-15 Schering Corporation Isolated dendritic cell membrane protein genes
US6537815B2 (en) 1997-07-11 2003-03-25 University Of North Texas, Health Science Center At Fort Worth Method of altering the expression of csrB to modify the properties of a cell
US6228638B1 (en) 1997-07-11 2001-05-08 University Of North Texas, Health Science Center At Fort Worth Escherichia coli CSRB gene and RNA encoded thereby
US20030190752A1 (en) * 1997-07-11 2003-10-09 Tony Romeo Escherichia coli csrB gene, RNA encoded thereby, and methods of use thereof
US20030180932A1 (en) * 1997-07-15 2003-09-25 Estell David A. Proteases from gram-positive organisms
US20050101001A1 (en) * 1997-07-15 2005-05-12 Estell David A. Proteases from gram-position organisms
US20050214816A1 (en) * 1997-07-15 2005-09-29 Estell David A Proteases from gram-positive organisms
US7329525B2 (en) 1997-07-15 2008-02-12 Genencor International, Inc. Serine proteases from gram-positive microorganisms
US6881562B2 (en) 1997-07-15 2005-04-19 Genencor International, Inc. Proteases from gram-positive organisms
US20050095683A1 (en) * 1997-07-15 2005-05-05 Estell David A. Proteases from gram-positive organisms
US6723550B1 (en) 1997-07-15 2004-04-20 Genencor International, Inc. Proteases from gram-positive organisms
US6506579B1 (en) 1997-07-15 2003-01-14 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms using SecG
US6833261B2 (en) 1997-07-15 2004-12-21 Genencor International, Inc. Proteases from gram-positive organisms
US20040126868A1 (en) * 1997-07-15 2004-07-01 Estell David A. Gram-positive microorganisms with an inactivated cysteine protease-3
US20030175892A1 (en) * 1997-07-15 2003-09-18 Estell David A. Proteases from gram-positive organisms
US20030166248A1 (en) * 1997-07-15 2003-09-04 Estell David A. Proteases from gram-positive organisms
US6849440B2 (en) 1997-07-15 2005-02-01 Genencor International, Inc. Proteases from gram-positive organisms
US6911333B2 (en) 1997-07-15 2005-06-28 Genencor International, Inc. Proteases from gram-positive organisms
US20030158070A1 (en) * 1997-07-15 2003-08-21 Estell David A. Proteases from gram-positive organisms
US20040137505A1 (en) * 1997-07-15 2004-07-15 Estell David A. Gram-positive microorganisms with an inactivated cysteine protease-2
US20030157642A1 (en) * 1997-07-15 2003-08-21 Caldwell Robert M. Increasing production of proteins in gram-positive microorganisms
US20050142638A1 (en) * 1997-07-15 2005-06-30 Estell David A. Proteases from gram-positive organisms
US7329526B2 (en) 1997-07-15 2008-02-12 Genencor International, Inc. Serine proteases from-gram-positive microorganisms
US7316920B2 (en) 1997-07-15 2008-01-08 Genencor International, Inc. Serine proteases from gram-positive microorganisms
US7329527B2 (en) 1997-07-15 2008-02-12 Genencor International, Inc. Serine proteases from gram-positive microorganisms
US20030124676A1 (en) * 1997-07-16 2003-07-03 Quax Wilhelmus J. Increasing production of proteins in gram-positive microorganisms
US7037714B2 (en) 1997-07-16 2006-05-02 Genencor International, Inc. Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US6521421B1 (en) 1997-07-16 2003-02-18 Genencor International, Inc. Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
EP2233574A1 (en) 1997-07-25 2010-09-29 Schering Corporation Mammalian cytokine: interleukin-B30 and related reagents
EP2100959A2 (en) 1997-07-25 2009-09-16 Schering Corporation Mammalian cytokine: interleukin-B30 and related reagents
EP1798287A2 (en) 1997-08-01 2007-06-20 Schering Corporation Mammalian cell membrane proteins and related reagents
US6180411B1 (en) 1997-08-01 2001-01-30 The Regents Of The University Of California Light-triggered indicators that memorize analyte concentrations
EP1798286A2 (en) 1997-08-01 2007-06-20 Schering Corporation Mammalian cell membrane proteins and related reagents
US7199234B2 (en) 1997-08-14 2007-04-03 Geron Corporation Regulatory segments of the human gene for telomerase reverse transcriptase
US20030204069A1 (en) * 1997-08-14 2003-10-30 Morin Gregg B. Segments of the human gene for telomerase reverse transcriptase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US20080096225A1 (en) * 1997-09-04 2008-04-24 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US20020127641A1 (en) * 1997-09-15 2002-09-12 Estell David A. Proteases from gram-positive organisms
US7326531B2 (en) 1997-09-15 2008-02-05 Genencor International, Inc. Proteases from gram-positive organisms
US6833265B2 (en) 1997-09-15 2004-12-21 Genencor International, Inc. Proteases from gram-positive organisms
US20050009146A1 (en) * 1997-09-15 2005-01-13 Estell David A. Proteases from gram-positive organisms
US6905868B2 (en) 1997-09-15 2005-06-14 Genencor International, Inc. Proteases from gram-positive organisms
US8101563B2 (en) 1997-09-15 2012-01-24 Danisco Us Inc. Proteases from gram-positive organisms
US7241575B2 (en) 1997-09-15 2007-07-10 Genecor International, Inc. Proteases from gram-positive organisms
US20050059112A1 (en) * 1997-09-15 2005-03-17 Estell David A. Proteases from gram-positive organisms
US20050106668A1 (en) * 1997-09-15 2005-05-19 Estell David A. Proteases from gram-positive organisms
US7189555B2 (en) 1997-09-15 2007-03-13 Genecor International, Inc. Proteases from gram-positive organisms
US6521440B1 (en) 1997-09-15 2003-02-18 Genencor International, Inc. Proteases from gram-positive organisms
US7220716B2 (en) 1997-09-15 2007-05-22 Genencor International, Inc. Proteases from gram-positive organisms
US20030113895A1 (en) * 1997-09-15 2003-06-19 Estell David A. Proteases from gram-positive organisms
US20050244925A1 (en) * 1997-09-15 2005-11-03 Estell David A Proteases from gram-positive organisms
US20060281106A1 (en) * 1997-10-01 2006-12-14 Andrews William H Telomerase promoter sequences for screening telomerase modulators
US20080220438A1 (en) * 1997-10-01 2008-09-11 Geron Corporation Telomerase Promoter Sequences for Screening Telomerase Modulators
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
US6482389B1 (en) 1997-10-17 2002-11-19 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
US6458557B1 (en) 1997-11-20 2002-10-01 Genencor International, Inc. Enhancing growth in gram-positive microorganisms using formate supplementation and inactivation of formate-associated transport proteins
US20020061580A1 (en) * 1997-11-20 2002-05-23 Estell David A. Alpha/beta hydrolase-fold enzymes
US20050249789A1 (en) * 1997-11-20 2005-11-10 Estell David A Alpha/beta hydrolase-fold enzymes
US20050014244A1 (en) * 1997-12-30 2005-01-20 Estell David A. Proteases from gram positive organisms
US7098021B2 (en) 1997-12-30 2006-08-29 Genencor International, Inc. Proteases from gram positive organisms
US20050019888A1 (en) * 1997-12-30 2005-01-27 Estell David A. Proteases from gram positive organisms
US20060035367A1 (en) * 1997-12-30 2006-02-16 Estell David A Proteases from gram positive organisms
US6599731B1 (en) 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US20050014227A1 (en) * 1997-12-30 2005-01-20 Estell David A. Proteases from gram positive organisms
US6872807B2 (en) 1997-12-30 2005-03-29 Genencor International, Inc. Proteases from gram positive organisms
US7070990B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from GRAM positive organisms
US20030078177A1 (en) * 1997-12-30 2003-04-24 Estell David A. Proteases from gram positive organisms
US7078216B2 (en) 1997-12-30 2006-07-18 Genencor International, Inc. Proteases from gram positive organisms
US7033817B2 (en) 1997-12-30 2006-04-25 Genencor International, Inc. Proteases from gram positive organisms
US7078372B2 (en) 1997-12-30 2006-07-18 Genencor International, Inc. Proteases from gram positive organisms
US20050089963A1 (en) * 1997-12-30 2005-04-28 Estell David A. Proteases from gram positive organisms
US7070986B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from gram positive organisms
US7070819B2 (en) 1997-12-30 2006-07-04 Genencor International, Inc. Proteases from gram positive organisms
US6794179B2 (en) 1997-12-30 2004-09-21 Genencor International, Inc. Proteases from gram positive organisms
US20050101504A1 (en) * 1997-12-30 2005-05-12 Estell David A. Proteases from gram positive organisms
US20050019887A1 (en) * 1997-12-30 2005-01-27 Estell David A. Proteases from gram positive organisms
US20050245417A1 (en) * 1997-12-30 2005-11-03 Estell David A Proteases from gram positive organisms
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7569357B2 (en) 1998-01-20 2009-08-04 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US7855075B2 (en) 1998-02-17 2010-12-21 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US8202724B2 (en) 1998-02-17 2012-06-19 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
US6060260A (en) * 1998-02-27 2000-05-09 Dade Behring Inc. Methods for reducing adsorption in an assay
WO1999045124A2 (en) 1998-03-04 1999-09-10 Genencor International, Inc. Modified forms of pullulanase
EP2295978A2 (en) 1998-03-20 2011-03-16 The Curators Of The University Of Missouri Early pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
US7192555B2 (en) 1998-03-30 2007-03-20 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US20070116597A1 (en) * 1998-03-30 2007-05-24 Mink Ronald W Device for collection and assay of oral fluids
EP1696236A2 (en) 1998-03-30 2006-08-30 OraSure Technologies, Inc. Device for assay of antibodies in oral fluids
US20020192839A1 (en) * 1998-03-30 2002-12-19 Epitope, Inc. Collection device for single step assay of oral fluids
US7541194B2 (en) 1998-03-30 2009-06-02 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US7846667B2 (en) 1998-03-31 2010-12-07 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
US20060275267A1 (en) * 1998-03-31 2006-12-07 Morin Gregg B Nucleic acids encoding inactive variants of human telomerase
US8796438B2 (en) 1998-03-31 2014-08-05 Geron Corporation Nucleic acids encoding inactive variants of human telomerase
US20110091892A1 (en) * 1998-03-31 2011-04-21 Genzyme Corporation Methods for the Diagnosis and Treatment of Lung Cancer
US20100062443A1 (en) * 1998-03-31 2010-03-11 Genzyme Corporation Methods for the Diagnosis and Treatment of Lung Cancer
US8067240B2 (en) 1998-03-31 2011-11-29 Esoterix Genetic Laboratories, Llc Methods for the diagnosis and treatment of lung cancer
US20070218511A1 (en) * 1998-03-31 2007-09-20 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
US7108968B2 (en) 1998-04-03 2006-09-19 Affymetrix, Inc. Mycobacterial rpoB sequences
US20020187467A1 (en) * 1998-04-03 2002-12-12 Thomas Gingeras Mycobacterial rpob sequences
US20060147964A1 (en) * 1998-04-03 2006-07-06 Affymetrix, Inc. Mycobacterial rpoB sequences
US6429304B1 (en) 1998-04-14 2002-08-06 The Regents Of The University Of California Nucleic acids encoding a katanin p60 subunit
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6410687B1 (en) 1998-04-14 2002-06-25 The Regents Of The University Of California Polypeptides for the detection of microtubule depolymerization inhibitors
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US7972638B2 (en) 1998-07-21 2011-07-05 Danisco A/S Foodstuff
US8163315B2 (en) 1998-07-21 2012-04-24 Danisco A/S Foodstuff
EP2058333A2 (en) 1998-07-23 2009-05-13 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6844433B2 (en) 1998-07-31 2005-01-18 Affymetrix, Inc. Nucleic acid labeling compounds
US20050164268A1 (en) * 1998-07-31 2005-07-28 Affymetrix, Inc. Nucleic acid labeling compounds
US20030232979A1 (en) * 1998-07-31 2003-12-18 Mcgall Glenn Nucleic acid labeling compounds
US7179905B2 (en) 1998-07-31 2007-02-20 Affymetrix, Inc. Nucleic acid labeling compounds
US20040002595A1 (en) * 1998-07-31 2004-01-01 Affymetrix, Inc. Nucleic acid labeling compounds
US7491818B2 (en) 1998-07-31 2009-02-17 Affymetrix, Inc. Nucleic acid labeling compounds
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
WO2000015824A1 (en) 1998-09-13 2000-03-23 Karolinska Innovations Ab Transfer method for specific cellular localisation of nucleic acids
US8013118B2 (en) 1998-09-18 2011-09-06 The Rockefeller University Lynx polypeptides
US20100004162A1 (en)